(i) ERISA. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of the Borrower under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of $50,000,000, or (ii) the Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of $125,000,000; or
(j) Invalidity of Loan Documents. Any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or satisfaction in full of all the Obligations, ceases to be in full force and effect; or the Borrower or any other Person contests in any manner the validity or enforceability of any Loan Document; or the Borrower denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any Loan Document; or
(k) Change of Control. There occurs any Change of Control with respect to the Borrower; or
(l) Loss of Licenses. (i) The Food and Drug Administration or any other Governmental Authority revokes or fails to renew any material license, permit, franchise, patent, trademark, service mark, trade name, copyright, authorization or other right of the Borrower or any Subsidiary, or the Borrower or any Subsidiary for any reason loses any material license, permit, franchise, patent, trademark, service mark, trade name, copyright, authorization or other right, or the Borrower or any Subsidiary suffers the imposition of any restraining order, escrow, suspension or impound of funds in connection with any proceeding (judicial or administrative) with respect to any material license, permit, franchise, patent, trademark, service mark, trade name, copyright, authorization or other right; and (ii) any event or circumstance described inclause (i) has resulted or is reasonably likely to result in a Material Adverse Effect.
8.02 Remedies Upon Event of Default. If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions:
(a) declare the commitment of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated;
(b) declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Borrower;
(c) require that the Borrower Cash Collateralize the L/C Obligations (in an amount equal to the then Outstanding Amount thereof); and
(d) exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan Documents or applicable law;
67
provided, however, that upon the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy Code of the United States, the obligation of each Lender to make Loans and any obligation of the L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Borrower to Cash Collateralize the L/C Obligations as aforesaid shall automatically become effective, in each case without further act of the Administrative Agent or any Lender.
8.03 Application of Funds. After the exercise of remedies provided for inSection 8.02 (or after the Loans have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso toSection 8.02), any amounts received on account of the Obligations shall, subject to the provisions ofSections 2.14 and2.15, be applied by the Administrative Agent in the following order:
First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including Attorney Costs and amounts payable underArticle III) payable to the Administrative Agent in its capacity as such;
Second, to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal and interest) payable to the Lenders (including Attorney Costs and amounts payable underArticle III), ratably among them in proportion to the amounts described in this clauseSecond payable to them;
Third, to payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans, L/C Borrowings and other Obligations, ratably among the Lenders and the L/C Issuer in proportion to the respective amounts described in this clauseThird payable to them;
Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans and L/C Borrowings, ratably among the Lenders and the L/C Issuer in proportion to the respective amounts described in this clauseFourth held by them;
Fifth, to the Administrative Agent for the account of the L/C Issuer, to Cash Collateralize that portion of L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit to the extent not otherwise Cash Collateralized by the Borrower pursuant toSections 2.03 and2.14; and
Last, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrower or as otherwise required by Law.
Subject toSections 2.03(c) and2.14, amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clauseFifth above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the other Obligations, if any, in the order set forth above.
68
ARTICLE IX.
ADMINISTRATIVE AGENT
9.01 Appointment and Authority. Each of the Lenders and the L/C Issuer hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuer, and the Borrower shall not have rights as a third party beneficiary of any of such provisions.
9.02 Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.
9.03 Exculpatory Provisions. The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, the Administrative Agent:
| |
| (a) shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing; |
| |
| (b) shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents),provided that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable law; and |
| |
| (c) shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. |
The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith
69
shall be necessary, under the circumstances as provided inSections 10.01 and8.02) or (ii) in the absence of its own gross negligence or willful misconduct. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent by the Borrower, a Lender or the L/C Issuer.
The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth inArticle IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.
9.04 Reliance by Administrative Agent. The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or the L/C Issuer, the Administrative Agent may presume that such condition is satisfactory to such Lender or the L/C Issuer unless the Administrative Agent shall have received notice to the contrary from such Lender or the L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.
9.05 Delegation of Duties. The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent.
9.06 Resignation of Administrative Agent. (a)The Administrative Agent may at any time give notice of its resignation to the Lenders, the L/C Issuer and the Borrower. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such
70
successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders and the L/C Issuer, appoint a successor Administrative Agent meeting the qualifications set forth above;provided that if the Administrative Agent shall notify the Borrower and the Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice and (1) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (2) all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and the L/C Issuer directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this Section. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section). The fees payable by the Borrower to a successor Administrative Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Article andSection 10.04 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent.
(b) Any resignation by Bank of America as Administrative Agent pursuant to this Section shall also constitute its resignation as L/C Issuer. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer, (b) the retiring L/C Issuer shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents, and (c) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to the retiring L/C Issuer to effectively assume the obligations of the retiring L/C Issuer with respect to such Letters of Credit.
9.07 Non-Reliance on Administrative Agent and Other Lenders. Each Lender and the L/C Issuer acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender and the L/C Issuer also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.
9.08 No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the Bookrunners, Arrangers, Syndication Agent or Co-Documentation Agents listed on the cover
71
page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Lender or the L/C Issuer hereunder.
9.09 Administrative Agent May File Proofs of Claim. In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to the Administrative Agent (irrespective of whether the principal of any Loan or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:
| |
| (a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the L/C Issuer and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the L/C Issuer and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders, the L/C Issuer and the Administrative Agent underSections 2.03(h) and(i),2.08 and10.04) allowed in such judicial proceeding; and |
| |
| (b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; |
and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and the L/C Issuer to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders and the L/C Issuer, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent underSections 2.08 and10.04.
Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or the L/C Issuer any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or the L/C Issuer to authorize the Administrative Agent to vote in respect of the claim of any Lender or the L/C Issuer in any such proceeding.
ARTICLE X.
MISCELLANEOUS
10.01 Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Borrower therefrom, shall be effective unless in writing signed by the Required Lenders and the Borrower, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given;provided, however, that no such amendment, waiver or consent shall:
72
(a) waive any condition set forth inSection 4.01(a) without the written consent of each Lender;
(b) extend or increase the Commitment of any Lender (or reinstate any Commitment terminated pursuant toSection 8.02) without the written consent of such Lender;
(c) postpone any date fixed by this Agreement or any other Loan Document for any payment of principal, interest, fees or other amounts due to the Lenders (or any of them) hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby;
(d) reduce the principal of, or the rate of interest specified herein on, any Loan or L/C Borrowing, or (subject toclause (iv) of the second proviso to thisSection 10.01) any fees or other amounts payable hereunder or under any other Loan Document, without the written consent of each Lender directly affected thereby;provided, however, that only the consent of the Required Lenders shall be necessary to amend the definition of “Default Rate” or to waive any obligation of the Borrower to pay interest or Letter of Credit Fees at the Default Rate;
(e) changeSection 8.03 in a manner that would alter the pro rata sharing of payments required thereby without the written consent of each Lender;
(f) change any provision of this Section or the definition of “Required Lenders” or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder, without the written consent of each Lender;
and,providedfurther, that (i) no amendment, waiver or consent shall, unless in writing and signed by the L/C Issuer in addition to the Lenders required above, affect the rights or duties of the L/C Issuer under this Agreement or any Issuer Document relating to any Letter of Credit issued or to be issued by it; (ii) no amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; and (iii)Section 10.06(h) may not be amended, waived or otherwise modified without the consent of each Granting Lender all or any part of whose Loans are being funded by an SPC at the time of such amendment, waiver or other modification; and (iv) the Fee Letter may be amended, or rights or privileges thereunder waived, in a writing executed only by the parties thereto. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender.
73
10.02 Notices; Effectiveness; Electronic Communication.
(a) Notices Generally. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided insubsection (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by telecopier as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows:
| |
| (i) if to the Borrower, the Administrative Agent or the L/C Issuer, to the address, telecopier number, electronic mail address or telephone number specified for such Person onSchedule 10.02; and |
| |
| (ii) if to any other Lender, to the address, telecopier number, electronic mail address or telephone number specified in its Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire then in effect for the delivery of notices that may contain material non-public information relating to the Borrower). |
Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices sent by telecopier shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for the recipient). Notices delivered through electronic communications to the extent provided insubsection (b) below, shall be effective as provided in suchsubsection (b).
(b) Electronic Communications. Notices and other communications to the Lenders and the L/C Issuer hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent,provided that the foregoing shall not apply to notices to any Lender or the L/C Issuer pursuant toArticle II if such Lender or the L/C Issuer, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it,provided that approval of such procedures may be limited to particular notices or communications.
Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement),provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoingclause (i) of notification that such notice or communication is available and identifying the website address therefor.
74
(c) The Platform. THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the Borrower, any Lender, the L/C Issuer or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Borrower’s or the Administrative Agent’s transmission of Borrower Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Agent Party;provided,however, that in no event shall any Agent Party have any liability to the Borrower, any Lender, the L/C Issuer or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages).
(d) Change of Address, Etc. Each of the Borrower, the Administrative Agent and the L/C Issuer may change its address, telecopier or telephone number for notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, telecopier or telephone number for notices and other communications hereunder by notice to the Borrower, the Administrative Agent and the L/C Issuer. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, telecopier number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender.
(e) Reliance by Administrative Agent, L/C Issuer and Lenders. The Administrative Agent, the L/C Issuer and the Lenders shall be entitled to rely and act upon any notices (including telephonic Loan Notices) purportedly given by or on behalf of the Borrower even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Borrower shall indemnify the Administrative Agent, the L/C Issuer, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Borrower. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.
10.03 No Waiver; Cumulative Remedies. No failure by any Lender, the L/C Issuer or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further
75
exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.
Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance withSection 8.02 for the benefit of all the Lenders and the L/C Issuer;provided,however, that the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b) the L/C Issuer from exercising the rights and remedies that inure to its benefit (solely in its capacity as L/C Issuer) hereunder and under the other Loan Documents, (c) any Lender from exercising setoff rights in accordance withSection 10.08 (subject to the terms ofSection 2.12), or (d) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Loan Party under any Debtor Relief Law; andprovided,further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant toSection 8.02 and (ii) in addition to the matters set forth inclauses (b),(c) and(d) of the preceding proviso and subject toSection 2.12, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.
10.04 Expenses; Indemnity; Damage Waiver.
(a) Costs and Expenses. The Borrower shall pay (i) all reasonable out of pocket expenses incurred by the Administrative Agent and its respective Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent), in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out of pocket expenses incurred by the L/C Issuer in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out of pocket expenses incurred by the Administrative Agent, any Lender or the L/C Issuer (including the fees, charges and disbursements of any counsel for the Administrative Agent, any Lender or the L/C Issuer), in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out of pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit.
(b) Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and the L/C Issuer, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, penalties, claims, damages,
76
liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder, the consummation of the transactions contemplated hereby or thereby or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Agreement and the other Loan Documents (including in respect of any matters addressed inSection 3.01), (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by the L/C Issuer to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by the Borrower or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, penalty, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower, and regardless of whether any Indemnitee is a party thereto;provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, penalties, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee or (y) result from a claim brought by the Borrower against an Indemnitee for breach in bad faith of such Indemnitee’s obligations hereunder or under any other Loan Document, if the Borrower has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction.
(c) Reimbursement by Lenders. To the extent that the Borrower for any reason fails to indefeasibly pay any amount required undersubsection (a) or(b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the L/C Issuer or any Related Party of any of the foregoing, but without affecting the obligations of the Borrower thereunder, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the L/C Issuer or such Related Party, as the case may be, such Lender’s Pro Rata Share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount,provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) or the L/C Issuer in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any such sub-agent) or L/C Issuer in connection with such capacity. The obligations of the Lenders under thissubsection (c) are subject to the provisions ofSection 2.11(d).
(d) Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, the Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof. No Indemnitee referred to insubsection (b) above shall be liable for any
77
damages arising from the use by unintended recipients of any information or other materials distributed to such unintended recipients by such Indemnitee through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the gross negligence or willful misconduct of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction.
(e) Payments. All amounts due under this Section shall be payable not later than ten Business Days after demand therefor.
(f) Survival. The agreements in this Section shall survive the resignation of the Administrative Agent and the L/C Issuer, the replacement of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations.
10.05 Payments Set Aside. To the extent that any payment by or on behalf of the Borrower is made to the Administrative Agent, the L/C Issuer or any Lender, or the Administrative Agent, the L/C Issuer or any Lender exercises its right of set-off, and such payment or the proceeds of such set-off or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent, the L/C Issuer or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such set-off had not occurred, and (b) each Lender and the L/C Issuer severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders and the L/C Issuer underclause (b) of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement.
10.06 Successors and Assigns.
(a) Successors and Assigns Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions ofsubsection (b) of this Section, (ii) by way of participation in accordance with the provisions ofsubsection (d) of this Section, (iii) by way of pledge or assignment of a security interest subject to the restrictions ofsubsection (f) of this Section, or (iv) to an SPC in accordance with the provisions ofsubsection (h) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided insubsection (d) of this Section and, to the extent
78
expressly contemplated hereby, the Related Parties of each of the Administrative Agent, the L/C Issuer and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.
(b) Assignments by Lenders. Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans (including for purposes of thissubsection (b), participations in L/C Obligations) at the time owing to it);provided that any such assignment shall be subject to the following conditions:
| | |
| (i) Minimum Amounts. |
| |
| (A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and the Loans at the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and |
| |
| (B) in any case not described insubsection (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $10,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed);provided,however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single Eligible Assignee (or to an Eligible Assignee and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met. |
| | |
| (ii) Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the Loans or the Commitment assigned. |
| |
| (iii) Required Consents. No consent shall be required for any assignment except to the extent required bysubsection (b)(i)(B) of this Section and, in addition: |
| | |
| | (A) the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; |
| | |
| | (B) the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required if such assignment is to a |
79
| | |
| | Person that is not a Lender, an Affiliate of such Lender or an Approved Fund with respect to such Lender; and |
| | |
| | (C) the consent of the L/C Issuer (such consent not to be unreasonably withheld or delayed) shall be required for any assignment that increases the obligation of the assignee to participate in exposure under one or more Letters of Credit (whether or not then outstanding). |
| | |
| (iv) Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500;provided,however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. |
| |
| (v) No Assignment to Certain Persons. No such assignment shall be made (A) to the Borrower or any of the Borrower’s Affiliates or Subsidiaries, or (B) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (B), or (C) to a natural person. |
| |
| (vi) Certain Additional Payments. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit in accordance with its Pro Rata Share. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs. |
Subject to acceptance and recording thereof by the Administrative Agent pursuant tosubsection (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning
80
Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits ofSections 3.01,3.04,3.05, and10.04 with respect to facts and circumstances occurring prior to the effective date of such assignment. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender, at which time any existing Note assigned to such Lender shall be redelivered to the Borrower. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance withsubsection (d) of this Section.
(c) Register. The Administrative Agent, acting solely for this purpose as an agent of the Borrower (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive, and the Borrower, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.
(d) Participations. Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person, a Defaulting Lender or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans (including such Lender’s participations in L/C Obligations) owing to it);provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent, the Lenders and the L/C Issuer shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement.
Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement;provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in the first proviso toSection 10.01 that directly affects such Participant. Subject tosubsection (e) of this Section, the Borrower agrees that each Participant shall be entitled to the benefits ofSections 3.01,3.04 and3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant tosubsection (b) of this Section. To the extent permitted by law, each Participant also shall be entitled to the benefits ofSection 10.08 as though it were a Lender,provided such Participant agrees to be subject toSection 2.12 as though it were a Lender.
81
(e) Limitations upon Participant Rights. A Participant shall not be entitled to receive any greater payment underSection 3.01 or3.04 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent. A Participant that would be a Foreign Lender if it were a Lender shall not be entitled to the benefits ofSection 3.01 unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply withSection 3.01(e) as though it were a Lender.
(f) Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank;provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.
(g) Electronic Execution of Assignments. The words “execution”, “signed”, “signature”, and words of like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
(h) Special Purpose Funding Vehicles. Notwithstanding anything to the contrary contained herein, any Lender (a “Granting Lender”) may grant to a special purpose funding vehicle identified as such in writing from time to time by the Granting Lender to the Administrative Agent and the Borrower (an “SPC”) the option to provide all or any part of any Loan that such Granting Lender would otherwise be obligated to make pursuant to this Agreement;provided that (i) nothing herein shall constitute a commitment by any SPC to fund any Loan, and (ii) if an SPC elects not to exercise such option or otherwise fails to make all or any part of such Loan, the Granting Lender shall be obligated to make such Loan pursuant to the terms hereof or, if it fails to do so, to make such payment to the Administrative Agent as is required underSection 2.11(b). Each party hereto hereby agrees that (i) neither the grant to any SPC nor the exercise by any SPC of such option shall increase the costs or expenses or otherwise increase or change the obligations of the Borrower under this Agreement (including its obligations underSection 3.04), (ii) no SPC shall be liable for any indemnity or similar payment obligation under this Agreement for which a Lender would be liable, and (iii) the Granting Lender shall for all purposes, including the approval of any amendment, waiver or other modification of any provision of any Loan Document, remain the lender of record hereunder. The making of a Loan by an SPC hereunder shall utilize the Commitment of the Granting Lender to the same extent, and as if, such Loan were made by such Granting Lender. In furtherance of the foregoing, each party hereto hereby agrees (which agreement shall survive the termination of this Agreement) that, prior to the date that is one year and one day after the payment in full of all outstanding commercial paper or other senior debt of any SPC, it will not institute against, or join any other Person in instituting against, such SPC any bankruptcy, reorganization,
82
arrangement, insolvency, or liquidation proceeding under the laws of the United States or any State thereof. Notwithstanding anything to the contrary contained herein, any SPC may (i) with notice to, but without prior consent of the Borrower and the Administrative Agent and with the payment of a processing fee in the amount of $3,500 (which processing fee may be waived by the Administrative Agent in its sole discretion), assign all or any portion of its right to receive payment with respect to any Loan to the Granting Lender and (ii) disclose on a confidential basis any non-public information relating to its funding of Loans to any rating agency, commercial paper dealer or provider of any surety or Guarantee or credit or liquidity enhancement to such SPC.
(i) Resignation as L/C Issuer after Assignment. Notwithstanding anything to the contrary contained herein, if at any time Bank of America assigns all of its Commitment and Loans pursuant tosubsection (b) above, Bank of America may, upon 30 days’ notice to the Borrower and the Lenders, resign as L/C Issuer. In the event of any such resignation as L/C Issuer, the Borrower shall be entitled to appoint from among the Lenders a successor L/C Issuer hereunder;provided,however, that no failure by the Borrower to appoint any such successor shall affect the resignation of Bank of America as L/C Issuer. If Bank of America resigns as L/C Issuer, it shall retain all the rights, powers, privileges and duties of the L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as L/C Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant toSection 2.03(c)). Upon the acceptance of a successor’s appointment as L/C Issuer hereunder, (a) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring L/C Issuer, (b) the retiring L/C Issuer shall be discharged from all of its respective duties and obligations hereunder or under the other Loan Documents, and (c) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit.
10.07 Treatment of Certain Information; Confidentiality. Each of the Administrative Agent, the Lenders and the L/C Issuer agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective partners, directors, officers, employees, agents, trustees, advisors and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (g) with the consent of the Borrower, (h) to any credit insurance provider relating to the Borrower and its Obligations or (i) to the extent such
83
Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, the L/C Issuer or any of their respective Affiliates on a nonconfidential basis from a source other than the Borrower.
For purposes of this Section, “Information” means all information received from the Borrower or any Subsidiary relating to the Borrower or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Lender or the L/C Issuer on a nonconfidential basis prior to disclosure by the Borrower or any Subsidiary,provided that, in the case of information received from the Borrower or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.
Each of the Administrative Agent, the Lenders and the L/C Issuer acknowledges that (a) the Information may include material non-public information concerning the Borrower or a Subsidiary, as the case may be, (b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including United States Federal and state securities Laws
10.08 Set-off. If an Event of Default shall have occurred and be continuing, each Lender, the L/C Issuer and each of their respective Affiliates is hereby authorized at any time and from time to time, without prior notice to the Borrower, any such notice being waived by the Borrower, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, the L/C Issuer or any such Affiliate to or for the credit or the account of the Borrower against any and all of the obligations of the Borrower now or hereafter existing under this Agreement or any other Loan Document to such Lender or the L/C Issuer, irrespective of whether or not such Lender or the L/C Issuer shall have made any demand under this Agreement or any other Loan Document and although such obligations of the Borrower may be contingent or unmatured or are owed to a branch or office of such Lender or the L/C Issuer different from the branch or office holding such deposit or obligated on such indebtedness; provided, that in the event that any Defaulting Lender shall exercise any such right of setoff on any amounts due on Obligations hereunder, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions ofSection 2.15 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender, the L/C Issuer and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender, the L/C Issuer or their respective Affiliates may have. Each Lender and the L/C Issuer agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application,provided that the failure to give such notice shall not affect the validity of such setoff and application.
84
10.09 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.
10.10 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Agreement and any other Loan Document by telecopy or electronic format (including .pdf) shall be effective as delivery of a manually executed counterpart of this Agreement and the other Loan Documents.
10.11 Integration. This Agreement, together with the other Loan Documents, comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control;provided that the inclusion of supplemental rights or remedies in favor of the Administrative Agent or the Lenders in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.
10.12 Survival of Representations and Warranties. All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding.
10.13 Severability. If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable
85
such provision in any other jurisdiction. Without limiting the foregoing provisions of thisSection 10.13, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent or the L/C Issuer, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited.
10.14 Replacement of Lenders.
(a) If any Lender requests compensation underSection 3.04, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant toSection 3.01, or if any Lender is a Defaulting Lender, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by,Section 10.06), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment),provided that:
| |
| (i) the Borrower shall have paid to the Administrative Agent the assignment fee specified inSection 10.06(b) (except as otherwise provided herein); |
| |
| (ii) such Lender shall have received payment of an amount equal to 100% of the outstanding principal of its Loans and L/C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts underSection 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); |
| |
| (iii) in the case of any such assignment resulting from a claim for compensation underSection 3.04 or payments required to be made pursuant toSection 3.01, such assignment will result in a reduction in such compensation or payments thereafter; and |
| |
| (iv) such assignment does not conflict with applicable Laws. |
(b) In the event any Lender fails to approve any amendment, waiver or consent requested by the Borrower pursuant toSection 10.01 that has received the written approval of not less than the Required Lenders but also requires the approval of such Lender (any such Lender, a “Restricted Lender”), so long as no Default or Event of Default shall have occurred and be continuing and the Borrower has obtained a commitment (in an amount not less than the entire amount of such Restricted Lender’s Commitment) from one or more Lenders or Eligible Assignees to become a Lender for all purposes hereunder (such Lender or Lenders referred to as the “Replacement Lender”), the Borrower may cause such Restricted Lender to be replaced by, and to assign all its rights and obligations under this Agreement (including its Commitment and its outstanding Credit Extensions) pursuant toSection 10.06 to, such Replacement Lender. Such Restricted Lender agrees to execute and to deliver to the Administrative Agent one or more Assignment and Assumptions with such Replacement Lender as provided inSection 10.06 upon
86
payment at par of all principal, accrued interest, accrued fees and other amounts accrued or owing under this Agreement to such Restricted Lender, and such Replacement Lender shall pay to the Administrative Agent the assignment fee specified inSection 10.06(b) in connection with such assignment. The Restricted Lender making such assignment will be entitled to compensation for any expenses or other amounts which would be owing to such Restricted Lender pursuant to any indemnification provision hereof (including, if applicable,Section 3.05) as if the Borrower has prepaid the Loans of such Lender (and terminated its Commitment, if applicable) rather than such Restricted Lender having assigned its interest hereunder.
A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.
10.15 Governing Law.
(a) THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE;PROVIDED THAT THE ADMINISTRATIVE AGENT AND EACH LENDER SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.
(b) ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW YORK CITY OR OF THE UNITED STATES FOR THE SOUTHERN DISTRICT OF SUCH STATE, AND BY EXECUTION AND DELIVERY OF THIS AGREEMENT, THE BORROWER, THE ADMINISTRATIVE AGENT AND EACH LENDER CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO THE NON-EXCLUSIVE JURISDICTION OF THOSE COURTS. THE BORROWER, THE ADMINISTRATIVE AGENT AND EACH LENDER IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OFFORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF ANY LOAN DOCUMENT OR OTHER DOCUMENT RELATED THERETO. THE BORROWER, THE ADMINISTRATIVE AGENT AND EACH LENDER WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY THE LAW OF SUCH STATE.
(c) EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES INSECTION 10.02. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.
10.16 Waiver of Right to Trial by Jury. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
87
AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.
10.17 No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower acknowledges and agrees, and acknowledges its Affiliates’ understanding, that: (i) (A) the arranging and other services regarding this Agreement provided by the Administrative Agent and the Arrangers, are arm’s-length commercial transactions between the Borrower and its respective Affiliates, on the one hand, and the Administrative Agent and the Arrangers, on the other hand, (B) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (ii) (A) the Administrative Agent and the Arrangers each is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower or any of its Affiliates, or any other Person and (B) neither the Administrative Agent nor the Arrangers has any obligation to the Borrower or any of its Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (iii) the Administrative Agent and the Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its Affiliates, and neither the Administrative Agent nor the Arrangers has any obligation to disclose any of such interests to the Borrower or its Affiliates. To the fullest extent permitted by law, the Borrower hereby waives and releases any claims that it may have against the Administrative Agent or any Arranger with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.
88
10.18 USA PATRIOT Act Notice. Each Lender that is subject to the Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it is required to obtain, verify and record information that identifies the Borrower, which information includes the name and address of the Borrower and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower in accordance with the Act. The Borrower shall, promptly following a request by the Administrative Agent or any Lender, provide all documentation and other information that the Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Act.
[The remainder of this page intentionally left blank.]
89
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.
| | |
| ST. JUDE MEDICAL, INC. |
| | |
| By: | /s/ John C. Heinmiller |
| Name: | John C. Heinmiller |
| Title: | Executive Vice President and Chief Financial Officer |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| BANK OF AMERICA, N.A., as Administrative Agent |
| | |
| By: | /s/ Angela Lau |
| Name: | Angela Lau |
| Title: | Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| BANK OF AMERICA, N.A., as a Lender and L/C Issuer |
| | |
| By: | /s/ Zubin R. Shroff |
| Name: | Zubin R. Shroff |
| Title: | Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| WELLS FARGO BANK, NATIONAL ASSOCIATION |
| | |
| By: | /s/ Scott Santa Cruz |
| Name: | Scott Santa Cruz |
| Title: | Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| THE BANK OF TOKYO-MITSUBISHI UFJ, LTD. |
| | |
| By: | /s/ Victor Pierzchalski |
| Name: | Victor Pierzchalski |
| Title: | Authorized Signatory |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| U.S. BANK NATIONAL ASSOCIATION |
| | |
| By: | /s/ Karen S. Paris |
| Name: | Karen S. Paris |
| Title: | Senior Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| THE ROYAL BANK OF SCOTLAND, PLC |
| | |
| By: | /s/ Timothy J. McNaught |
| Name: | Timothy J. McNaught |
| Title: | Managing Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| MIZUHO CORPORATE BANK (USA) |
| | |
| By: | /s/ Raymond Ventura |
| Name: | Raymond Ventura |
| Title: | Deputy General Manager |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| SVENSKA HANDELSBANKEN AB (PUBL)
NEW YORK BRANCH |
| | |
| By: | /s/ Richard Johnson |
| Name: | Richard Johnson |
| Title: | Senior Vice President |
| | |
| By: | /s/ Mark Emmett |
| Name: | Mark Emmett |
| Title: | Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| SUMITOMO MITSUI BANKING CORPORATION |
| | |
| By: | /s/ William M. Ginn |
| Name: | William M. Ginn |
| Title: | Executive Officer |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| TD BANK, N.A. |
| | |
| By: | /s/ Marla Willner |
| Name: | Marla Willner |
| Title: | Senior Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| BNP PARIBAS |
| | |
| By: | /s/ Michael Pearce |
| Name: | Michael Pearce |
| Title: | Director |
| | |
| By: | /s/ Andy Strait |
| Name: | Andy Strait |
| Title: | Managing Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| JPMORGAN CHASE BANK, N.A. |
| | |
| By: | /s/ Brian L. Grossman |
| Name: | Brian L. Grossman |
| Title: | Senior Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| SUNTRUST BANK |
| | |
| By: | /s/ Elizabeth Greene |
| Name: | Elizabeth Greene |
| Title: | Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| FIFTH THIRD BANK |
| | |
| By: | /s/ Joshua N. Livingston |
| Name: | Joshua N. Livingston |
| Title: | Officer |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| LLOYDS TSB BANK PLC |
| | |
| By: | /s/ Windsor R. Davies |
| Name: | Windsor R. Davies |
| Title: | Managing Director, Corporate Banking USA D061 |
| | |
| By: | /s/ Candi Obrentz |
| Name: | Candi Obrentz |
| Title: | Vice President, Financial Institutions, North America O013 |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| PNC BANK, NATIONAL ASSOCIATION |
| | |
| By: | /s/ Philip K. Liebscher |
| Name: | Philip K. Liebscher |
| Title: | Senior Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| COMERICA BANK |
| | |
| By: | /s/ Brandon Welling |
| Name: | Brandon Welling |
| Title: | Assistant Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| KBC BANK N.V. |
| | |
| By: | /s/ Kurt O. Pagon |
| Name: | Kurt O. Pagon |
| Title: | Vice President |
| | |
| By: | /s/ Robert Snauffer |
| Name: | Robert Snauffer |
| Title: | Managing Director |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| BANK OF COMMUNICATIONS CO., LTD., NEW YORK BRANCH |
| | |
| By: | /s/ Shelley He |
| Name: | Shelley He |
| Title: | Deputy General Manager |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| THE NORTHERN TRUST COMPANY |
| | |
| By: | /s/ Benjamin Livermore |
| Name: | Benjamin Livermore |
| Title: | Vice President |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| CHANG HWA COMMERCIAL BANK, LTD., LOS ANGELES BRANCH |
| | |
| By: | /s/ Beverley Chen |
| Name: | Beverley Chen |
| Title: | Vice President & General Manager |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
| | |
| MEGA INTERNATIONAL COMMERCIAL BANK CO., LTD., NEW YORK BRANCH |
| | |
| By: | /s/ Priscilla Hsing |
| Name: | Priscilla Hsing |
| Title: | VP & DGM |
St. Jude Medical, Inc.
Multi-Year Credit Agreement
Signature Page
SCHEDULE 1.01
EXCLUDED SUBSIDIARIES
None
S-1
SCHEDULE 2.01
COMMITMENTS
AND PRO RATA SHARES
| | | | | | | | |
Lender | | Commitment | | | Pro Rata Share | |
Bank of America, N.A. | | $ | 140,000,000.00 | | | | 9.333333333 | % |
Wells Fargo Bank, National Association | | $ | 140,000,000.00 | | | | 9.333333333 | % |
The Bank of Tokyo-Mitsubishi UFJ, Ltd. | | $ | 140,000,000.00 | | | | 9.333333333 | % |
U.S. Bank National Association | | $ | 87,500,000.00 | | | | 5.833333333 | % |
The Royal Bank of Scotland, plc | | $ | 87,500,000.00 | | | | 5.833333333 | % |
Mizuho Corporate Bank (USA) | | $ | 70,000,000.00 | | | | 4.666666667 | % |
Svenska Handelsbanken AB (PUBL) New York Branch | | $ | 70,000,000.00 | | | | 4.666666667 | % |
Sumitomo Mitsui Banking Corporation | | $ | 70,000,000.00 | | | | 4.666666667 | % |
TD Bank, N.A. | | $ | 70,000,000.00 | | | | 4.666666667 | % |
BNP Paribas | | $ | 70,000,000.00 | | | | 4.666666667 | % |
JPMorgan Chase Bank, N.A. | | $ | 65,000,000.00 | | | | 4.333333333 | % |
SunTrust Bank | | $ | 65,000,000.00 | | | | 4.333333333 | % |
Fifth Third Bank | | $ | 65,000,000.00 | | | | 4.333333333 | % |
Lloyds TSB Bank plc | | $ | 65,000,000.00 | | | | 4.333333333 | % |
PNC Bank, National Association | | $ | 65,000,000.00 | | | | 4.333333333 | % |
Comerica Bank | | $ | 50,000,000.00 | | | | 3.333333333 | % |
KBC Bank N.V. | | $ | 50,000,000.00 | | | | 3.333333333 | % |
Bank of Communications Co. Ltd., New York Branch | | $ | 50,000,000.00 | | | | 3.333333333 | % |
The Northern Trust Company | | $ | 40,000,000.00 | | | | 2.666666667 | % |
Chang Hwa Commercial Bank, Ltd., Los Angeles Branch | | $ | 25,000,000.00 | | | | 1.666666667 | % |
Mega International Commercial Bank Co., Ltd., New York Branch | | $ | 15,000,000.00 | | | | 1.000000000 | % |
Total | | $ | 1,500,000,000.00 | | | | 100.000000000 | % |
S-2
SCHEDULE 5.05
LITIGATION
Judicial Matters:
Silzone® Litigation and Insurance Receivables: The Borrower has been sued in various jurisdictions beginning in March 2000 by some patients who received a heart valve product with Silzone® coating, which the Borrower stopped selling in January 2000. Some of these claimants allege bodily injuries as a result of an explant or other complications, which they attribute to these products. Others, who have not had their Silzone-coated heart valve explanted, seek compensation for past and future costs of special monitoring they allege they need over and above the medical monitoring all other replacement heart valve patients receive. Some of the lawsuits seeking the cost of monitoring have been initiated by patients who are asymptomatic and who have no apparent clinical injury to date. The Borrower has vigorously defended against the claims that have been asserted and expects to continue to do so with respect to any remaining claims. While the Borrower has a small number of individual Silzone cases in federal and state courts outstanding, based on the Borrower’s historical experience with similar cases, the Borrower expects to resolve these specific cases at minimal, if any, cost to the Borrower.
The Borrower has been able to successfully resolve class action matters relating to Silzone in British Columbia and Quebec. As part of the British Columbia class action settlement, the Borrower made a $2.1 million payment in March 2010. As part of the Quebec class action settlement, the Borrower made a $5.7 million payment in April 2010. The Quebec class action settlement also resolved the claim raised by the Quebec Provincial health insurer seeking to recover the cost of insured services furnished or to be furnished to class members in the Quebec class action.
The Borrower has two outstanding class action cases relating to Silzone in Ontario and one individual case in British Columbia by the Provincial health insurer. In Ontario, a class action case involving Silzone patients has been certified, and the trial began in February 2010. A second case seeking class action status in Ontario has been stayed pending resolution of the other Ontario class action. The complaints in the Ontario cases request damages up to 2.0 billion Canadian Dollars (the equivalent of $1.9 billion at October 2, 2010). Based on the Borrower’s historical experience, the amount ultimately paid, if any, often does not bear any relationship to the amount claimed. The British Columbia Provincial health insurer has a lawsuit seeking to recover the cost of insured services furnished or to be furnished to class members in the British Columbia class action, and that lawsuit remains pending in the British Columbia court.
The Borrower has recorded an accrual for probable legal costs, settlements and judgments for Silzone related litigation. The Borrower is not aware of any unasserted claims related to Silzone-coated products. For all Silzone legal costs incurred, the Borrower records insurance receivables for the amounts that it expects to recover. Any costs (the material components of which are settlements, judgments, legal fees and other related defense costs) not covered by the Borrower’s product liability insurance policies or existing reserves could be material to the Borrower’s consolidated earnings, financial position and cash flows. The following table summarizes the Borrower’s Silzone legal accrual and related insurance receivables at October 2, 2010 and January 2, 2010 (in thousands):
S-3
| | | | | | | |
| | October 2, 2010 | | January 2, 2010 | |
| | | | | |
Silzone legal accrual | | $ | 23,133 | | $ | 23,326 | |
| | | | | | | |
Silzone insurance receivable | | $ | 63,710 | | $ | 42,538 | |
Part of the Borrower’s remaining product liability insurance for Silzone claims consists of a $50.0 million layer of insurance covered by American Insurance Borrower (AIC). In December 2007, AIC initiated a lawsuit in Minnesota federal district court seeking a court order declaring that it is not required to provide coverage for a portion of the Silzone litigation defense and indemnity expenses that the Borrower may incur in the future. The insurance broker that assisted the Borrower in procuring the insurance with AIC was also added as a party to the case on the Borrower’s behalf. The Borrower and AIC have now agreed to settle this litigation.
Part of the Borrower’s final layer of insurance was covered by Lumberman’s Mutual Casualty Insurance, a unit of the Kemper Insurance Companies (collectively referred to as Kemper). Kemper is currently in “run off,” which means it is no longer issuing new policies, and therefore, is not generating any new revenue that could be used to cover claims made under previously-issued policies. In September 2010, Kemper agreed to settle its future insurance obligations with the Borrower, the amount of which was not material. The Borrower’s remaining insurance for Silzone claims consists of $30 million of coverage with other insurance carriers that are responsible for claims incurred after the AIC insurance layer is exhausted. To the extent that the Borrower’s future Silzone costs and expenses exceed our remaining insurance coverage, the Borrower would be responsible for such costs. The Borrower has not accrued for any potential losses relating to future costs as they are not probable or reasonably estimable at this time.
Volcano Corporation & LightLab Imaging Litigation: The Borrower’s recently acquired subsidiary, LightLab Imaging, Inc. (LightLab Imaging), has pending litigation with Volcano Corporation (Volcano) and Axsun Technologies, Inc. (Axsun), a subsidiary of Volcano, in state court in Massachusetts and Delaware. LightLab Imaging makes and sells optical coherence tomography (OCT) imaging systems. Volcano is a LightLab Imaging competitor in medical imaging. Axsun makes and sells lasers and is a supplier of lasers to LightLab Imaging for use in OCT imaging systems. The lawsuits arise out of Volcano’s acquisition of Axsun in December 2008. Before Volcano acquired Axsun, LightLab Imaging and Axsun had worked together to develop a tunable laser for use in OCT imaging systems. While the laser was in development, LightLab Imaging and Axsun entered into an agreement pursuant to which Axsun agreed to sell its tunable lasers exclusively to LightLab in the field of human coronary artery imaging for a period of years.
After Volcano acquired Axsun in December 2008, LightLab Imaging sued Axsun and Volcano
S-4
in Massachusetts, asserting a number of claims arising out of Volcano’s acquisition of Axsun. In a phased trial in Massachusetts in February 2010, a jury found Axsun had breached its contract with LightLab Imaging, Volcano had intentionally interfered with that contract, and both Axsun and Volcano had misappropriated certain LightLab Imaging trade secrets. The jury also found Axsun was contractually required to sell a particular version of the laser to LightLab Imaging, rejecting Axsun’s position that the contract only required the sale of an earlier version of the laser. The jury also found in LightLab Imaging’s favor that the restriction on sales of tunable lasers to Volcano applied to all of Axsun’s tunable lasers for OCT imaging, rejecting Axsun’s and Volcano’s position that the restriction on such sales applied only to a laser meeting a particular specification. Following the jury’s verdict, LightLab Imaging, Axsun, and Volcano stipulated to the amount of damages a jury could award against Axsun and Volcano.
In a later phase of the Massachusetts lawsuit, the court ruled there was an insufficient basis to enjoin Axsun and Volcano from using certain information, not considered by the jury, that LightLab Imaging regards as trade secrets. LightLab Imaging presently expects the court will consider other trade secret issues in later stages, as well as considering whether Axsun’s and Volcano’s conduct constituted knowing or willful violations of a statute that prohibits unfair or deceptive acts or practices or acts of unfair competition, whether damages against Axsun or Volcano should be doubled or trebled under that statute, whether Axsun and Volcano should be ordered to reimburse LightLab Imaging for its attorneys fees and related litigation expenses, and whether any permanent injunctions should be entered against Axsun and Volcano.
In Delaware, Axsun and Volcano commenced an action in February 2010 against LightLab Imaging, seeking a declaration as to whether Axsun may supply a certain light source for use in OCT imaging systems to Volcano. Axsun’s and Volcano’s position is that this light source is not a tunable laser and hence falls outside Axsun’s exclusivity obligations to LightLab Imaging. LightLab Imaging’s position, among other things, is that this light source is a tunable laser. The parties are presently involved in expedited discovery, and a trial is expected to commence in early to mid 2011.
Volcano Corporation & St. Jude Medical Patent Litigation: In July 2010, the Borrower filed a lawsuit in federal district court in Delaware against Volcano for patent infringement. The suit involves five patents and seeks injunctive relief and monetary damages. The infringed patents are used for the St. Jude Medical PressureWire® technology platform, which was acquired from Radi Medical Systems in December 2008. In September 2010, Volcano filed counterclaims against the Borrower, alleging certain St. Jude Medical patent claims are unenforceable and that certain St. Jude Medical products infringe three Volcano patents. The Borrower believes the assertions and claims made by Volcano are without merit.
Boston U.S. Attorney Investigation: In October 2005, the U.S. Department of Justice (DOJ), acting through the U.S. Attorney’s office in Boston, commenced an industry-wide investigation into whether the provision of payments and/or services by makers of implantable cardioverter-defibrillators (ICDs) and bradycardia pacemaker systems (pacemakers) to doctors or other persons constitutes improper inducements under the federal health care program anti-kickback law. As part of this investigation, the Borrower has received three subpoenas from the DOJ requesting documents regarding the Borrower’s practices related to ICDs, pacemakers, lead systems and related products marketed by the Borrower’s Cardiac Rhythm Management (CRM) operating segment. The Borrower has cooperated with the investigation and has produced
S-5
documents and witnesses as requested. In January 2010, the U.S. District Court for the District of Massachusetts unsealed a qui tam action (private individual bringing suit on behalf of the U.S. Government) filed by a former employee containing allegations relating to the issues covered by the subpoenas. Although in December 2009, the DOJ had declined to intervene in this qui tam suit, the DOJ filed a motion in August 2010 to intervene. The Court granted the DOJ’s motion, without prejudice to the Borrower. The DOJ has indicated that it intends only to pursue alleged claims related to four post-market studies conducted by the Borrower primarily in 2004-2006. The Court also ruled that the Borrower may file its objection to the August 2010 DOJ intervention and argue that the DOJ has not established good cause to intervene. At a status hearing on November 29, 2010, the Court directed DOJ to file its complaint by January 31, 2011. The Borrower will vigorously defend against the allegations in the lawsuit. It is not possible to predict the outcome of this matter at this time.
Additionally, in December 2008, the U.S. Attorney’s Office in Boston delivered a subpoena issued by the Office of Inspector General requesting the production of documents relating to implantable cardiac rhythm device and pacemaker warranty claims. The Borrower has cooperated with the investigation and has produced documents as requested.
U.S. Department of Justice - Civil Investigative Demand: In March 2010, the Borrower received a Civil Investigative Demand (CID) from the Civil Division of the DOJ. The CID requests documents and sets forth interrogatories related to communications by and within the Borrower on various indications for ICDs and a National Coverage Decision issued by Centers for Medicare and Medicaid Services. Similar requests were made of our major competitors. The Borrower is cooperating with the investigation and is continuing to work with the DOJ in responding to the CID.
Securities Class Action Litigation:On March 18, 2010, a securities class action lawsuit was filed in federal district court in Minnesota against the Borrower and certain officers on behalf of purchasers of the Borrower’s common stock between April 22, 2009 and October 6, 2009. The lawsuit relates to the Borrower’s earnings announcements for the first, second and third quarters of 2009, as well as a preliminary earnings release dated October 6, 2009. The complaint, which seeks unspecified damages and other relief as well as attorneys’ fees, alleges that the Borrower failed to disclose that it was experiencing a slowdown in demand for its products and was not receiving anticipated orders for CRM devices. Class members allege that the Borrower’s failure to disclose the above information resulted in the class purchasing the Borrower’s stock at an artificially inflated price. The Borrower intends to vigorously defend against the claims asserted in this lawsuit. In October 2010, the Borrower filed a motion to dismiss the lawsuit, which is scheduled to be heard by the District Court in early January 2011.
Derivative Litigation:In September 2010, two separate derivative actions involving the Borrower were filed in the United States District Court for the District of Minnesota. In both of these matters, the defendants consist of members (or former members) of the Borrower’s Board of Directors as well as various officers and former officers of the Borrower. The plaintiffs in these actions are asserting breach of fiduciary duty claims against the named defendants for their purported failure to stop the alleged underlying conduct (which relates to the contents of qui tam actions filed in Ohio and Massachusetts). In October 2010, the plaintiffs filed a motion before the Judicial Panel on MultiDistrict Litigation requesting that the two cases be transferred to the District of Massachusetts and consolidated with what they claim are related actions there. The Borrower intends to oppose the transfer request and to vigorously defend against the claims
S-6
asserted in these two derivative lawsuits.
Regulatory Matters
The Food and Drug Administration (FDA) inspected the Borrower’s manufacturing facility in Minnetonka, Minnesota at various times between December 8 and December 19, 2008. On December 19, 2008, the FDA issued a Form 483 identifying certain observed non-conformities with current Good Manufacturing Practice (cGMP) primarily related to the manufacture and assembly of the SafireTM ablation catheter with a 4 mm or 5 mm non-irrigated tip. Following the receipt of the Form 483, the Borrower’s Atrial Fibrillator division provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address the FDA’s observations of non-conformity. The Borrower subsequently received a warning letter dated April 17, 2009 from the FDA relating to these non-conformities with respect to this facility.
The FDA inspected the Borrower’s Plano, Texas manufacturing facility at various times between March 5 and April 6, 2009. On April 6, 2009, the FDA issued a Form 483 identifying certain observed nonconformities with cGMP. Following the receipt of the Form 483, the Borrower’s Neuromodulation division provided written responses to the FDA detailing proposed corrective actions and immediately initiated efforts to address the FDA’s observations of nonconformity. The Borrower subsequently received a warning letter dated June 26, 2009 from the FDA relating to these non-conformities with respect to its Neuromodulation division’s Plano, Texas and Hackettstown, New Jersey facilities.
With respect to each of these warning letters, the FDA notes that it will not grant requests for exportation certificates to foreign governments or approve pre-market approval applications for Class III devices to which the quality system regulation deviations are reasonably related until the violations have been corrected. The Borrower is working cooperatively with the FDA to resolve all of its concerns.
On April 23, 2010, the FDA issued a warning letter based upon a July 29, 2009 inspection of our Sunnyvale, California facility and a review of our website. The warning letter cites the Borrower for its promotion and marketing of the Epicor™ LP Cardiac Ablation System and the Epicor UltraCinch LP Ablation Device based on certain statements made in the Borrower’s marketing materials. The Borrower is working cooperatively with the FDA to resolve all of its concerns. The warning letter is not expected to have any material impact on the Borrower’s business.
Customer orders have not been and are not expected to be impacted while the Borrower works to resolve the FDA’s concerns. The Borrower is working diligently to respond timely and fully to the FDA’s requests. While the Borrower believes the issues raised by the FDA can be resolved without a material impact on the Borrower’s financial results, the FDA has recently been increasing its scrutiny of the medical device industry and raising the threshold for compliance. The government is expected to continue to scrutinize the industry closely with inspections, and possibly enforcement actions, by the FDA or other agencies. The Borrower is regularly monitoring, assessing and improving its internal compliance systems and procedures to ensure that its activities are consistent with applicable laws, regulations and requirements, including those of the FDA.
Other Matters
S-7
In connection with the pending acquisition of AGA Medical Holdings, Inc. (AGA Medical), the Borrower, in addition to AGA Medical and other defendants, has been named as a defendant in two putative stockholder class action complaints, one filed in the Fourth Judicial District Court of Minnesota on October 27, 2010 and the other filed in the Delaware Court of Chancery on October 28, 2010. The plaintiffs in the complaints allege, among other claims, that AGA Medical’s directors breached their fiduciary duties to AGA Medical’s stockholders by accepting an inadequate price, failing to make full disclosure, and utilizing unreasonable deal protection devices and further alleges that AGA Medical and the Borrower aided and abetted the purported breaches of fiduciary duty. The complaints seek injunctive relief, including to enjoin the transaction, in addition to unspecified compensatory damages, attorneys’ fees, other fees and costs and other relief. On November 8, 2010, the parties to this action entered into a memorandum of understanding (MOU) to settle the litigation. The settlement contemplated by the MOU is subject to several conditions, including the negotiation and execution of a stipulation of settlement and the approval of the Delaware Court of Chancery.
As part of the acquisition of AGA Medical Holdings, Inc. that closed on November 18, 2010, the Borrower inherited a Deferred Prosecution Agreement arising from Foreign Corrupt Practices Act issues in China. The Deferred Prosecution Agreement is limited to AGA Medical and its subsidiaries and expires on June 8, 2011.
On November 9, 2010, the French Competition Authorities conducted a “dawn raid” on the offices of the Borrower’s French subsidiary as part of a CRM industry wide investigation into certain pricing practices. The Borrower is cooperating with the investigation.
The Borrower is also involved in various other lawsuits, claims and proceedings that arise in the ordinary course of business.
S-8
SCHEDULE 5.07
ERISA MATTERS
None
S-9
SCHEDULE 5.10
TAXES
The Borrower and St. Jude Medical Puerto Rico, Inc. (SJMPR) received “30-day” letters and examination reports on IRS Form 870 dated November 20, 2008 from the Internal Revenue Service (IRS) proposing adjustments to each of the Borrower’s and SJMPR’s taxes for the periods 1998-2005 and 1998-1999. The Borrower and SJMPR each filed a protest of the proposed adjustments on January 22, 2009, and have had a series of ongoing meetings with IRS Appeals to try to resolve the issue. The proposed adjustments arise from transfer pricing issues related to transactions between the Borrower and SJMPR. The Borrower and SJMPR disagree with the proposed adjustment and intend to contest this matter through applicable IRS and judicial procedures, as appropriate.
S-10
SCHEDULE 5.11
MATERIAL INDEBTEDNESS
The Borrower’s Subsidiaries in Spain and Italy have initiated letters of credit with various banks in the ordinary course of business. These letters of credit total approximately $35 million.
The Borrower maintains a large deductible workers’ compensation insurance program and foreign liability program for which insurance carriers require collateral in the form of a standby letter of credit. These letters of credit currently total approximately $6.5 million.
As of December 14, 2010, the Borrower has approximately $21 million outstanding under the Borrower’s commercial paper program.
On December 6, 2010, the Borrower issued $500.0 million principal amount of 5-year, 2.50% unsecured senior notes that mature in January 2016. Concurrent with the issuance of the 2016 Senior Notes, the Borrower entered into a 5-year, $500.0 million notional amount interest rate swap designated as a fair value hedge of the changes in fair value of the Borrower’s fixed-rate 2016 Senior Notes.
S-11
SCHEDULE 5.12
ENVIRONMENTAL MATTERS
None
S-12
SCHEDULE 5.16
SUBSIDIARIES
St. Jude Medical, Inc.
Subsidiaries and Equity Investments
as of December 10, 2010
Part (a)
| | | | | |
St. Jude Medical, Inc. Wholly Owned Subsidiaries: |
• | AGA Medical Holdings, Inc. – Plymouth, Minnesota (Delaware corporation) |
| | - | AGA Medical Corporation – Plymouth, Minnesota (Minnesota corporation) |
| | - | Amplatzer Medical Sales Corporation – Plymouth, Minnesota (Minnesota corporation) |
| | | | - | AGA Medical (HK) Limited – (Chinese private limited Borrower) |
| | | | - | AGA Medical, LLC – Plymouth, Minnesota (Minnesota corporation) |
| | - | AGA Medical Switzerland Sárl –(Swiss limited liability Borrower) |
| | - | AGA Medical Limited – (United Kingdom corporation) |
| | - | AGA Medical Deutschland GmbH – (German corporation) |
| | - | Amplatzer Medical España, S.L. – (Spanish limited liability Borrower) |
| | - | Amplatzer Medical France SAS – (French corporation) |
| | - | AGA Medical Polska Sp. zo.o. – (Polish corporation) |
| | - | AGA Medical Canada Inc. – (Canadian corporation) |
| | - | AGA Medical Italia S.R.L. – (Italian limited liability Borrower) |
| | - | Amplatzer Medical Portugal, Unipessoal Lda. – (Portuguese limited liability Borrower) |
| | - | AGA Medical Belgium Sprl – (Belgian limited liability Borrower) |
• | Pacesetter, Inc. – Sylmar, California, Scottsdale, Arizona, and Maven, South Carolina (Delaware corporation) (dba St. Jude Medical Cardiac Rhythm Management Division) |
• | St. Jude Medical S.C., Inc. – Austin, Texas (Minnesota corporation) |
• | St. Jude Medical Europe, Inc. – St. Paul, Minnesota (Delaware corporation) |
• | St. Jude Medical Canada, Inc. – Mississauga, Ontario (Ontario, Canada corporation) |
• | St. Jude Medical (Shanghai) Co., Ltd. – Shanghai, China (Chinese corporation) |
| - | Beijing, Shanghai and Guangzhou representative offices |
• | St. Jude Medical Australia Pty., Ltd. – Sydney, Australia (Australian corporation) |
• | St. Jude Medical Brasil, Ltda. – Sao Paulo and Belo Horizonte, Brazil (Brazilian corporation) |
• | St. Jude Medical, Atrial Fibrillation Division, Inc. (Formerly St. Jude Medical, Daig Division, Inc.) - Minnesota and California (Minnesota corporation) |
| - | Endocardial Solutions NV/SA (Belgian corporation) |
| - | EP MedSystems France (French corporation) |
• | St. Jude Medical Colombia, Ltda. – Bogota, Colombia (Colombian corporation) |
• | Eagle Merger Corporation – (Delaware corporation) |
• | St. Jude Medical ATG, Inc. – Maple Grove, Minnesota (Minnesota corporation) (Shell) |
• | St. Jude Medical (Thailand) Co., Ltd. – Bangkok, Thailand (Thai corporation) |
• | Irvine Biomedical, Inc. – Irvine, California (California corporation) |
• | St. Jude Medical, Cardiology Division, Inc. (Formerly Velocimed, Inc.) - Minnesota (Delaware corporation) (dba St. Jude Medical Cardiovascular Division) |
| - | LightLab Imaging, Inc. – Westford, Massachusetts (Delaware corporation) |
| | | | - | LightLab Imaging Europe B.V. (Dutch corporation) |
| - | Sealing Solutions, Inc. – Plymouth, Minnesota (Georgia corporation) |
• | SJ Medical Mexico, S. de R.L. de C.V. – (Mexican corporation) |
S-13
| | | | | |
• | St. Jude Medical Argentina S.A. – Buenos Aires, Argentina (Argentinean corporation) |
• | Advanced Neuromodulation Systems, Inc. – Plano, Texas (Texas Corporation) (dba St. Jude Medical Neuromodulation Division) |
| - | Hi-Tronics Designs, Inc. – Budd Lake, New Jersey (New Jersey Corporation) |
• | SJM International, Inc. – St. Paul, Minnesota (Delaware corporation) |
| | | | | |
SJM International, Inc. Wholly Owned Legal Entities (Directly and Indirectly): |
• | SJM Delaware Holding, LLC – St. Paul, Minnesota (Delaware Limited Liability Borrower) |
• | St. Jude Medical Bermuda GP (Bermuda partnership) (SJM International, Inc. is the majority partner and SJM Delaware Holding LLC is the minority partner) |
| - | St. Jude Medical Luxembourg Holding S.à r.l. (Luxembourg corporation) |
| | - | U.S. Branch of St. Jude Medical Luxembourg Holding S.à r.l. |
| | | - | MediGuide, LLC (Delaware limited liability Borrower) |
| | | | - | MediGuide Ltd. (Israeli corporation) |
| | - | St. Jude Medical Nederland B.V. (Netherlands corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | - | St. Jude Medical Puerto Rico LLC (Puerto Rican corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | - | St. Jude Medical AB (Swedish corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | | - | St. Jude Medical Systems AB (formerly Radi Medical Systems AB) (Swedish corporation) |
| | | | - | Radi Medical Systems Ltd. (United Kingdom corporation) |
| | | | - | Radi Medical Systems Co., Ltd. (Thai corporation) |
| | | | - | Radi Medical Systems Pte., Ltd. (Singaporean corporation) |
| | | - | HB Betakonsult (Swedish partnership) (St. Jude Medical AB holds a 99% interest and St. Jude Medical Systems AB holds a 1% interest) |
| | - | SJM Coordination Center BVBA (Belgian corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | | - | Cardio Life Research S.A. (Belgian corporation) |
| | | - | St. Jude Medical Balkan d.o.o. (Serbian corporation) |
| | | - | St. Jude Medical Estonia OÜ (Estonian corporation) |
| | - | St. Jude Medical Operations (Malaysia) Sdn. Bhd. (Malaysian corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | - | St. Jude Medical Costa Rica Limitada (Costa Rica corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | - | St. Jude Medical Holdings B.V. (Netherlands corporation) (wholly owned subsidiary of St. Jude Medical Luxembourg Holding S.à r.l.) |
| | | - | St. Jude Medical Japan Co., Ltd. (Japanese corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V.) |
| | | - | St. Jude Medical India Private Limited (Indian corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V.) |
| | | - | St. Jude Medical (Singapore) Pte. Ltd. (Singaporean corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V.) |
| | | - | St. Jude Medical (Malaysia) Sdn Bhd (Malaysian corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V.) |
| | | - | St. Jude Medical Taiwan Co. (Taiwan corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V.) |
| | | - | St. Jude Medical Korea YH (Korean corporation) (wholly owned subsidiary of St. Jude Medical Holdings B.V. |
S-14
| | | | |
| | | - | St. Jude Medical (Hong Kong) Limited - Central, Hong Kong (Hong Kong corporation) |
| |
• | St. Jude Medical Sweden AB (Swedish corporation) |
• | St. Jude Medical Danmark A/S (Danish corporation) |
• | St. Jude Medical (Portugal) - Distribuição de Produtos Médicos, Lda. (Portuguese corporation) |
• | St. Jude Medical Export Ges.m.b.H. (Austrian corporation) |
• | St. Jude Medical Medizintechnik Ges.m.b.H. (Austrian corporation) |
• | St. Jude Medical Italia S.p.A. (Italian corporation) |
• | St. Jude Medical Belgium (Belgian corporation) |
• | St. Jude Medical España S.A. (Spanish corporation) |
• | St. Jude Medical France S.A.S. (French corporation) |
• | St. Jude Medical Finland O/y (Finnish corporation) |
• | St. Jude Medical Sp.zo.o. (Polish corporation) |
• | St. Jude Medical GmbH (German corporation) |
• | St. Jude Medical Kft (Hungarian corporation) |
• | St. Jude Medical UK Limited (United Kingdom corporation) |
• | St. Jude Medical (Schweiz) AG (Swiss corporation) |
• | UAB “St. Jude Medical Baltic” (Lithuanian corporation) |
• | St. Jude Medical Norway AS (Norwegian corporation) |
Part (b)
The following sets forth, as of the Closing Date, the Borrower’s equity investments in any other corporation or entity other than as permitted pursuant to Section 7.04(e):
None
S-15
SCHEDULE 6.06
INSURANCE COVERAGE
| | | | | | |
Coverage | | Limits | | Retention | | Insurance Companies |
| | | | | | |
Commercial Property/earthquake | | Based on valuation $3 billion aggregate | | Various | | FM Global |
| | | | | | |
General Liability | | $ 2 million aggregate $ 1 million/occurrence | | Various | | Sentry Insurance |
| | | | | | |
Auto Insurance | | $ 1 million | | $ 1,000 | | Sentry Insurance |
| | | | | | |
Workers’ Compensation | | Statutory | | $ 750,000 | | Sentry Insurance |
| | | | | | |
Umbrella | | $ 30 million | | Underlying policy | | Zurich |
| | | | | | |
Foreign DIC etc. | | Various | | Various | | ACE |
| | | | | | |
Directors & Officers | | $ 75 million | | $ 10 million (Securities claims) $5 million other claims | | ACE XL Chartis Axis WR Berkley Chubb XL |
| | | | | | |
Crime | | $10 million | | $ 250,000 | | National Union |
| | | | | | |
Cargo | | Various | | $ 100,000 | | Ace INA |
| | | | | | |
Fiduciary | | $ 15 million | | $ 100,000 | | Chubb |
S-16
SCHEDULE 7.01
EXISTING LIENS
In December 2008, Borrower (through its affiliates) acquired a Swedish-based medical device company, Radi Medical Systems and all of its subsidiaries, including Radi Medical Systems Co., Ltd,. a Thailand corporation (“Radi Thailand”). As part of such transaction, pursuant to the Amended and Restated Option Agreement, dated as of December 9, 2009 (the “Option Agreement”), among St. Jude Medical AB, St. Jude Medical (Thailand) Co., Ltd., Radi Medical Systems AB and Engstrom Holdings Pte. Ltd. (“Engstrom Holdings”), Engstrom Holdings has been granted the right and option to repurchase the stock of Radi Thailand, currently a wholly-owned subsidiary of the Borrower, pursuant to the terms of the Option Agreement. In addition, in connection with the Option Agreement, the stock of Radi Thailand was placed into an escrow account and Engtrom Holdings was granted a first priority pledge over the stock held in such escrow account.
S-17
SCHEDULE 7.04(a)
ST. JUDE MEDICAL, INC.
GLOBAL INVESTMENT POLICY
Effective December 2009
|
PURPOSE |
This investment policy (Policy) describes the objectives of and provides guidelines for investment of funds on behalf of St. Jude Medical, Inc. and all of its legal entities (Borrower). The Policy also defines the employees authorized to engage in investment activity (“Authorized Individuals), authorized investment sources (Authorized Brokers/Issuers), authorized investment managers (Authorized Managers), and portfolio quality, diversification and maturity parameters. Modification of or deviation from the Policy requires the approval of the Audit Committee of the Board of Directors of the Borrower (Audit Committee), except for changes in Authorized Individuals, Authorized Brokers/Issuers, or Authorized Managers, which require the prior written approval of the Borrower’s Chief Financial Officer and either the Treasurer or Assistant Treasurer. |
This policy does not supersede the Borrower’s Banking Resolution. Any banks listed as Authorized Brokers/Issuers for the purpose of this Policy refer to the investment or investment brokerage entity or function within that bank or investment bank, but not to the depository, lending function or organization which is the subject of the Banking Resolution.
| |
Investment Objectives |
The Borrower has three primary investment objectives, in priority order: |
| |
1. | Preservation of principal |
2. | Liquidity |
3. | Competitive after-tax yield |
| |
Authorized Individuals |
1. | Chief Executive Officer |
2. | Chief Operating Officer |
3. | Chief Financial Officer |
4. | Treasurer |
5. | Assistant Treasurer |
6. | Manager of Treasury Operations |
7. | Sr. Treasury Analyst |
8. | Other designees as approved in writing by the Chief Executive Officer or the Chief Financial Officer and either the Treasurer or Assistant Treasurer |
S-18
|
Authorized Investments |
Authorized investments, minimum quality characteristics, maximum allowable maturities and allowable concentration (percentage of investment portfolio) parameters are described in Exhibit A of the Policy. In general, investment activity is restricted to investment grade securities, with minimum rating(s) on trade date by Standard & Poor’s as outlined in Exhibit A of the Policy, or the equivalent rating from Moody’s, or Fitch. Investments must be currency neutral, i.e. investments must be made in the reporting currency or the currency that is already held by the entity completing the investment. |
|
Authorized Brokers/Issuers |
Authorized Individuals are restricted to utilizing brokers, banks and direct issuers of commercial paper as described in Exhibit B of the Policy. A current version of Exhibit B indicating all additions or deletions from the list of Authorized Brokers/Issuers is to be maintained by the Treasurer or Assistant Treasurer. A written agreement signed by the Borrower’s Chief Financial Officer and Treasurer or Assistant Treasurer is required for each Authorized Broker/Issuer prior to executing investment transactions. |
|
Authorized Managers |
Authorized Managers are described in Exhibit C of the Policy. Authorized Managers are restricted to investments as detailed in Exhibit A of the Policy. Authorized Managers are required to utilize broker dealers providing best execution of trades, “best execution” being defined as most favorable pricing at lowest cost. A written agreement signed by the Borrower’s Chief Financial Officer and Treasurer or Assistant Treasurer is required for each Authorized Manager prior to executing investment transactions. This written agreement will contain an addendum documenting selection of security custodians and appropriate performance benchmarks mutually chosen by the Authorized Manager and the Borrower. |
| | |
Responsibility |
1. | Audit Committee |
| a. | Annual review of investment activity and results |
| b. | Annual review of the Borrower’s internally prepared compliance report |
| | |
2. | Chief Financial Officer |
| a. | Annual review of the Policy |
| b. | Overall compliance with the Policy |
| c. | Approval of any changes in Authorized Individuals or Authorized Brokers/Issuers or Authorized Managers |
| d. | Execution of agreements with Authorized Brokers/Issuers and Authorized Managers |
| e. | Distribution of annual investment and audit reports to the Audit Committee |
| f. | Decision on appropriate remedial strategy regarding any investment where that investments’ value may be affected because of a negative credit rating change subsequent to purchase. |
| | |
3. | Treasurer or Assistant Treasurer |
| a. | Direct responsibility for compliance with the Policy |
| b. | On at least a quarterly basis, review the list of Authorized Brokers/Issuers and Authorized Managers and recommend revisions |
S-19
| | |
| c. | Approval of any changes in Authorized Individuals or Authorized Brokers/Issuers or Authorized Managers (also requires CFO approval) |
| d. | Execution of agreements with Authorized Brokers/Issuers or Authorized Managers |
| e. | Distribution of periodic reports to management |
| f. | As soon as known by the Treasurer or Assistant Treasurer, report to the Chief Financial Officer any negative credit rating change that may affect any existing investments’ value. This report shall include viable elections with respect to the investment of concern |
| | |
4. | Authorized Individuals |
| a. | Ongoing compliance with the Policy |
| b. | Preparation of accurate and timely reports for management and the Audit Committee |
| c. | As soon as known by the Individual, report to the Treasurer or Assistant Treasurer any negative credit rating change of any existing investment |
| | |
5. | Internal Audit Function |
| a. | Preparation and distribution of an annual compliance audit for the Audit Committee |
S-20
| |
Reporting Requirements |
1. | Annual investment report to the Audit Committee |
2. | Monthly report to Chief Financial Officer, Treasurer and Controller |
3. | Annual compliance audit report |
4. | Other as directed by management |
| |
Equity Investments |
At the direction of the Chief Executive Officer of the Borrower, Authorized Individuals are permitted to purchase up to $25 million in aggregate of the capital stock, or equivalent, in a non-affiliated Borrower. Amounts in excess of $25 million in aggregate require approval by the Board of Directors. |
| |
Without further approval of the Board of Directors, the Chief Executive Officer may direct authorized individuals to sell or otherwise dispose of investments in non-affiliated companies. |
| |
Management Savings Plan (MSP) Investments |
The Borrower maintains certain investments such as life insurance contracts and mutual funds that serve to hedge the Borrower’s obligations under its MSP. This Global Investment Policy is not intended to govern the management of the MSP investments. |
| |
Duration |
This Policy is subject to annual review by the Audit Committee. |
S-21
ST JUDE MEDICAL, INC.
INVESTMENT POLICY
EXHIBIT A
AUTHORIZED INVESTMENTS
| | | | |
Instrument | Minimum Rating on trade date (S&P or Equiv.) | Expected Average Life | Maximum Exposure Per Issue/Issuer On trade date |
| | See Definitions and Clarifications below table |
| Bank certificates of deposit | | | |
| | | | |
| Wells Fargo | AAA | 90 days | $100 million or 5% of |
| Bank of America | AA | 90 days | portfolio |
| JP Morgan | AA | 90 days | $75 million or 5% of |
| Bank of Tokyo Mitsubishi | A | 90 days | portfolio |
| Svenska Handelsbanken | AA | 90 days | $75 million or 5% of |
| | | | portfolio |
| All other banks: | A | 90 days | $50 million or 5% of |
| | | | portfolio |
| | AA | 90 days | $75 million or 5% of |
| | | | portfolio |
| | | | |
| | | | A rated - $20 million or 5% |
| | | | of portfolio |
| | | | AA rated $50 million or 5% |
| | | | of portfolio |
| Yankee certificates of deposit | A | 90 days | A rated - $20 million or 5% of portfolio |
| | AA | 90 days | AA rated - $50 million or |
| | | | 5% of portfolio |
| Bankers’ acceptances | A2 | 180 days | $20 million or 5% of |
| | | | portfolio |
| Commercial paper | A1 | 270 days | $40 million or 5% of |
| | | | portfolio |
| | | | |
| | A2 | 60 days | |
| | | | $20 million or 5% of |
| | | | portfolio |
| Asset backed commercial paper | A2 | 60days | $20 million or 5% of portfolio |
| Asset backed securities | AAA | 1 year | $20 million or 5% of |
| | | | portfolio |
| Corporate bonds or notes | AA | Two years | $20 million or 5% of |
| | | | portfolio |
S-22
| | | | |
| | | | |
| Money market funds | AAA | N/A | $50 million or 5% of |
| | | | portfolio |
| Liquidity vehicles/money | A1 | 90 days | $20 million or 5% of |
| market equivalents | | | portfolio |
| | | | |
| Municipal bonds or notes | A | One year | $20 million or 5% of |
| | | | portfolio |
| Municipal variable rate notes | SP-2 | 14 days | $20 million or 5% of |
| | | | portfolio |
| Repurchase agreements | AA | 7 days | $20 million or 5% of |
| | | | portfolio |
| U.S. government agencies | N/A | Three | N/A |
| | | years | |
| U.S. government obligations | N/A | Three | N/A |
| | | years | |
S-23
Definitions and Clarifications
For Investments Managed Internally By St. Jude
Minimum rating on trade date:
| | |
| • | For Split rated securities, the lowest of the ratings is used |
| • | Repurchase agreements must be collateralized by U.S. Government or Agency securities |
Expected average life:
| | | | |
| • | Investments managed internally shall be governed solely by the Expected Average Life in the table above. For securities which have put dates or reset dates the first put date or first reset date will be used instead of the final legal maturity date. |
| | | | |
| | The following criteria will be used for purposes of determining Expected Average Life: |
| | | o | The next reset date will be used for floating rate securities, the put date for putable securities, the call date for securities trading on a yield-to-call basis, and the average life on securities with periodic principal payments prior to maturity such as mortgage backed securities and asset backed securities. |
| | | o | The final legal maturity date of any single issue cannot exceed 3 years from the date of purchase. |
Maximum exposure per issue/issuer on trade date:
| | | | |
| • | St. Jude investments managed internally shall be governed solely by the $ maximum exposure limits per issue/issuer outlined in the table above and: |
| | | o | Shall be consolidated for all SJM entities |
| | | o | Shall be consolidated for each issue/issuer |
| | | o | Shall consist of principal only |
| | | | |
| • | To determine maximum exposure per issue/issuer for investments denominated in currencies other than US$: |
| | | o | A spot exchange rate shall be obtained from Reuters on the investment trade date |
| | | o | A foreign currency equivalent maximum shall be calculated using the rate obtained and the US$ maximum from the table above |
For Investments Managed Externally (by Authorized Managers):
| | |
| • | Maximum exposure limits [for any single issue/issuer] are 5% of the portfolio under management |
S-24
| | |
| • | Investments shall be managed such that the final legal maturity of a security is no more than 5 years from date of purchase, with an overall average duration of the portfolio to be no longer than 18 months |
| • | Investments shall be managed to an overall portfolio quality rating of AA or better |
| • | No single investment shall be rated lower than A- at time of purchase |
| • | Authorized investment instruments are listed in the table Exhibit A. |
| • | Repurchase agreements must be collateralized by U.S. Government or Agency securities. |
S-25
ST. JUDE MEDICAL, INC.
INVESTMENT POLICY
EXHIBIT B
AUTHORIZED BROKERS/ISSUERS
| |
| |
| Commercial Banks / Brokers |
| Banco Popular |
| Bank of America |
| JP Morgan |
| Wells Fargo |
| KBC Bank |
| Canadian Imperial Bank of Commerce |
| Svenska Handelsbanken |
| Suntrust |
| Northern Trust |
| Comerica Bank |
| Sumitomo Mitsui |
| Royal Bank of Scotland |
| TD Banks |
| US Bank |
| Fifth Third |
| Piper Jaffray |
| PNC Bank |
| Mizuho Corporate Bank |
S-26
ST. JUDE MEDICAL, INC.
INVESTMENT POLICY
EXHIBIT C
AUTHORIZED MANAGERS
Bank of America Capital Management, Inc.
Wells Capital Management
Northern Trust Investments
S-27
SCHEDULE 7.05
EXISTING INDEBTEDNESS
None
S-28
SCHEDULE 10.02
ADMINISTRATIVE AGENT’S OFFICE,
CERTAIN ADDRESSES FOR NOTICES
BORROWER:
St. Jude Medical, Inc.
One Lillehei Plaza
St. Paul, Minnesota 55117
Attention: Robert Frenz
Telephone: 651-481-7661
Facsimile: 651-490-4333
Electronic Mail: rfrenz@sjm.com
U.S. Taxpayer Identification Number: 41-1276891
ADMINISTRATIVE AGENT:
Administrative Agent’s Office
(for payments and Requests for Credit Extensions):
Bank of America, N.A.
101 N. Tryon Street
Mail Code: NC1-001-04-39
Charlotte, NC 28255
Attention: James Hood
Telephone: 980-386-4308
Telecopier: 704-409-0599
Electronic Mail:james.p.hood @baml.com
Account No.: 1366212250600
Attn: Credit Services
Ref: St. Jude Medical, Inc.
ABA# 026009593
Other Notices as Administrative Agent:
Bank of America, N.A.
Agency Management
1455 Market Street, 5th Floor
Mail Code: CA5-701-05-19
San Francisco, CA 94103
Attention: Angela Lau
Telephone: 415-436-4000
Telecopier: 415-503-5008
Electronic Mail:angela.lau@baml.com
S-29
with a copy to:
Bank of America, N.A.
Corporate Debt Products
100 N. Tryon Street
Mail Code: NC1-007-17-11
Charlotte, NC 28255
Attention: Zubin Shroff
Telephone: 980-387-1340
Telecopier: 704-804-5415
Electronic Mail:zubin.r.shroff @baml.com
L/C ISSUER:
Bank of America, N.A.
Trade Operations
1000 W. Temple Street
Mail Code: CA9-705-07-05
Los Angeles, CA 90012
Attention: Stella Rosales
Telephone: 213-481-7828
Telecopier: 213-457-8841
Electronic Mail:stella.rosales @baml.com
S-30
EXHIBIT A
FORM OF LOAN NOTICE
Date: ___________, _____
To: Bank of America, N.A., as Administrative Agent
Ladies and Gentlemen:
Reference is made to that certain Multi-Year $1,500,000,000 Credit Agreement, dated as of December 22, 2010 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Agreement”; the terms defined therein being used herein as therein defined), among St. Jude Medical, Inc., a Minnesota corporation (the “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent and L/C Issuer.
The undersigned hereby requests (select one):
o A Borrowing of Loans o A conversion or continuation of Loans
| | | |
| 1. | On ______________________________ (a Business Day). |
| | |
| 2. | In the amount of $_______________. |
| | |
| 3. | Comprised of ________________________________________. |
| | [Type of Loan requested] | |
| | |
| 4. | For Eurodollar Rate Loans: with an Interest Period of __________ months. |
The Borrowing requested herein complies with the proviso to the first sentence ofSection 2.01 of the Agreement.
| | |
| ST. JUDE MEDICAL, INC. |
| | |
| By: | |
A-1
Form of Loan Notice
EXHIBIT B
FORM OF NOTE
____________________
FOR VALUE RECEIVED, the undersigned (the “Borrower”), hereby promises to pay to _____________________ or registered assigns (the “Lender”), in accordance with the provisions of the Agreement (as hereinafter defined), the principal amount of each Loan from time to time made by the Lender to the Borrower under that certain Multi-Year $1,500,000,000 Credit Agreement, dated as of December 22, 2010 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Agreement”; the terms defined therein being used herein as therein defined), among the Borrower, the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent and L/C Issuer.
The Borrower promises to pay interest on the unpaid principal amount of each Loan from the date of such Loan until such principal amount is paid in full, at such interest rates and at such times as provided in the Agreement. All payments of principal and interest shall be made to the Administrative Agent for the account of the Lender in Dollars in immediately available funds at the Administrative Agent’s Office. If any amount is not paid in full when due hereunder, such unpaid amount shall bear interest, to be paid upon demand, from the due date thereof until the date of actual payment (and before as well as after judgment) computed at the per annum rate set forth in the Agreement.
This Note is one of the Notes referred to in the Agreement, is entitled to the benefits thereof and may be prepaid in whole or in part subject to the terms and conditions provided therein. Upon the occurrence and continuation of one or more of the Events of Default specified in the Agreement, all amounts then remaining unpaid on this Note shall become, or may be declared to be, immediately due and payable all as provided in the Agreement. Loans made by the Lender shall be evidenced by one or more loan accounts or records maintained by the Lender in the ordinary course of business. The Lender may also attach schedules to this Note and endorse thereon the date, amount and maturity of its Loans and payments with respect thereto.
The Borrower, for itself, its successors and assigns, hereby waives diligence, presentment, protest and demand and notice of protest, demand, dishonor and non-payment of this Note.
THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.
| | |
| ST. JUDE MEDICAL, INC. |
| | |
| By: | |
B-1
Form of Note
LOANS AND PAYMENTS WITH RESPECT THERETO
| | | | | | | | | | | | |
Date | | Type of Loan Made | | Amount of Loan Made | | End of Interest Period | | Amount of Principal or Interest Paid This Date | | Outstanding Principal Balance This Date | | Notation Made By |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
________ | | __________ | | __________ | | __________ | | __________ | | __________ | | ________ |
B-2
Form of Note
EXHIBIT C
FORM OF COMPLIANCE CERTIFICATE
Financial Statement Date: __________, _____
To: Bank of America, N.A., as Administrative Agent
Ladies and Gentlemen:
Reference is made to that certain Multi-Year $1,500,000,000 Credit Agreement, dated as of December 22, 2010 (as amended, restated, extended, supplemented or otherwise modified in writing from time to time, the “Agreement”; the terms defined therein being used herein as therein defined), among St. Jude Medical, Inc., a Minnesota corporation (the “Borrower”), the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent and L/C Issuer.
The undersigned Responsible Officer hereby certifies as of the date hereof that he/she is the _____________________________________________ of the Borrower, and that, as such, he/she is authorized to execute and deliver this Certificate to the Administrative Agent on the behalf of the Borrower, and that:
[Use following paragraph 1 for fiscalyear-end financial statements]
1. Attached hereto asSchedule 1 are the year-end audited financial statements required bySection 6.01(a) of the Agreement for the fiscal year of the Borrower ended as of the above date, together with the report and opinion of an independent certified public accountant required by such section.
[Use following paragraph 1 for fiscal quarter-end financial statements]
1. Attached hereto asSchedule 1 are the unaudited financial statements required bySection 6.01(b) of the Agreement for the fiscal quarter of the Borrower ended as of the above date. Such financial statements fairly present the financial condition, results of operations and cash flows of the Borrower and its Subsidiaries in accordance with GAAP as at such date and for such period, subject only to normal year-end audit adjustments and the absence of footnotes.
2. The undersigned has reviewed and is familiar with the terms of the Agreement and has made, or has caused to be made under his/her supervision, a detailed review of the transactions and condition (financial or otherwise) of the Borrower during the accounting period covered by the attached financial statements.
3. A review of the activities of the Borrower during such fiscal period has been made under the supervision of the undersigned with a view to determining whether during such fiscal period the Borrower performed and observed all its Obligations under the Loan Documents, and
C-1
Form of Compliance Certificate
[select one:]
[to the best knowledge of the undersigned during such fiscal period, the Borrower performed and observed each covenant and condition of the Loan Documents applicable to it.]
--or--
[the following covenants or conditions have not been performed or observed and the following is a list of each such Default and its nature and status:]
4. The representations and warranties of the Borrower contained inArticle V of the Agreement, but excluding the representation and warranty as to no Material Adverse Effect contained inSection 5.11(b) of the Agreement, or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, are true and correct on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that for purposes of this Compliance Certificate, the representations and warranties contained insubsection (a) ofSection 5.11 shall be deemed to refer to the most recent statements furnished pursuant toclauses (a) and(b), respectively, ofSection 6.01 of the Agreement, including the statements in connection with which this Compliance Certificate is delivered.
5. The financial covenant analyses and information set forth onSchedule 2 attached hereto are true and accurate on and as of the date of this Certificate.
IN WITNESS WHEREOF, the undersigned has executed this Certificate as of _______________, _____.
| | | | |
| ST. JUDE MEDICAL, INC. |
| |
| By: | |
| Name: | |
| Title: | |
| | |
C-2
Form of Compliance Certificate
For the Quarter/Year ended ___________________ (“Statement Date”)
SCHEDULE 2
to the Compliance Certificate
($ in 000’s)
| | | | | | | |
I. | Section 7.13 – Consolidated Leverage Ratio. | | | | |
| | | | | |
| A. | Consolidated EBITDA for four consecutive fiscal quarters ending on above date (“Subject Period”): | | | | |
| | 1. | Consolidated Net Income for Subject Period: | | $ | | |
| | 2. | Consolidated Interest Charges for Subject Period: | | $ | | |
| | 3. | Provision for income taxes for Subject Period: | | $ | | |
| | 4. | Depreciation expenses for Subject Period: | | $ | | |
| | 5. | Amortization expenses for intangibles for Subject Period: | | $ | | |
| | 6. | Non-cash expenses reducing Consolidated Net Income for Subject Period: | | $ | | |
| | 7. | Non-cash items increasing Consolidated Net Income for Subject Period: | | $ | | |
| | 8. | Consolidated EBITDA (Lines I.A.1 + 2 + 3 + 4 + 5 + 6 - 7): | | $ | | |
| | | | | | |
| B. | Consolidated Funded Indebtedness at Statement Date: | | $ | | |
| | | | | | |
| C. | Consolidated Leverage Ratio (Line I.B ÷ Line I.A): | | | _______to 1 | |
| | | | | | |
| | Maximum permitted: | | | 3.0 to 1.0 | �� |
C-3
Form of Compliance Certificate
EXHIBIT D
FORM OF
ASSIGNMENT AND ASSUMPTION AGREEMENT
This Assignment and Assumption (this “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into by and between [the][each]1 Assignor identified in item 1 below ([the][each, an] “Assignor”) and[the][each]2 Assignee identified in item 2 below ([the][each, an] “Assignee”).[It is understood and agreed that the rights and obligations of [the Assignors][the Assignees]3 hereunder are several and not joint.]4 Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (the “Credit Agreement”), receipt of a copy of which is hereby acknowledged by the Assignee. The Standard Terms and Conditions set forth inAnnex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein in full.
For an agreed consideration,[the][each] Assignor hereby irrevocably sells and assigns to[the Assignee][the respective Assignees], and[the][each] Assignee hereby irrevocably purchases and assumes from[the Assignor][the respective Assignors], subject to and in accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent as contemplated below (i) all of[the Assignor’s][the respective Assignors’] rights and obligations in[its capacity as a Lender][their respective capacities as Lenders] under the Credit Agreement and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of[the Assignor][the respective Assignors] under the respective facilities identified below (including, without limitation, the Letters of Credit included in such facilities) and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of[the Assignor (in its capacity as a Lender)][the respective Assignors (in their respective capacities as Lenders)] against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any of the foregoing, including, but not limited to, contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations sold and assigned by[the][any] Assignor to[the][any] Assignee pursuant to clauses (i) and (ii) above
1 For bracketed language here and elsewhere in this form relating to the Assignor(s), if the assignment is from a single Assignor, choose the first bracketed language. If the assignment is from multiple Assignors, choose the second bracketed language.
2 For bracketed language here and elsewhere in this form relating to the Assignee(s), if the assignment is to a single Assignee, choose the first bracketed language. If the assignment is to multiple Assignees, choose the second bracketed language.
3Select as appropriate.
4Include bracketed language if there are either multiple Assignors or multiple Assignees.
D-4
Form of Assignment and Assumption Agreement
being referred to herein collectively as[the][an] “Assigned Interest”). Each such sale and assignment is without recourse to[the][any] Assignor and, except as expressly provided in this Assignment and Assumption, without representation or warranty by[the][any] Assignor.
| | |
1. | Assignor[s]: | |
|
| | |
|
2. | Assignee[s]: | |
|
| | |
| | |
| [for each Assignee, indicate [Affiliate][Approved Fund] of [identify Lender]] |
| | |
3. | Borrower: | St. Jude Medical, Inc. |
| | |
4. | Administrative Agent: Bank of America, N.A., as the administrative agent under the Credit Agreement |
| |
5. | Credit Agreement: Multi-Year $1,500,000,000 Credit Agreement, dated as of December 22, 2010, among St. Jude Medical, Inc., the Lenders from time to time party thereto, and Bank of America, N.A., as Administrative Agent and L/C Issuer |
| |
6. | Assigned Interest[s]: |
| | | | | | | | | | | | | | | | |
Assignor[s]5 | | Assignee[s]6 | | Aggregate Amount of Commitment for all Lenders7 | | Amount of Commitment Assigned | | Percentage Assigned of Commitment8 | | CUSIP Number | |
| | | | | | | | | | | | | | | | |
| | | | | $ | ________ | | $ | ________ | | ________ | % | | | | |
| | | | | $ | ________ | | $ | ________ | | ________ | % | | | | |
| | | | | $ | ________ | | $ | ________ | | ________ | % | | | | |
| |
[7. | Trade Date: __________________]9 |
5List each Assignor, as appropriate.
6List each Assignee, as appropriate.
7 Amounts in this column and in the column immediately to the right to be adjusted by the counterparties to take into account any payments or prepayments made between the Trade Date and the Effective Date.
8Set forth, to at least 9 decimals, as a percentage of the Commitment of all Lenders thereunder.
9To be completed if the Assignor and the Assignee intend that the minimum assignment amount is to be determined as of the Trade Date.
D-5
Form of Assignment and Assumption Agreement
Effective Date: __________________, 20__ [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]
The terms set forth in this Assignment and Assumption are hereby agreed to:
| | |
| ASSIGNOR |
| | |
| [NAME OF ASSIGNOR] |
| | |
| By: | |
| | Title: |
| | |
| ASSIGNEE |
| | |
| [NAME OF ASSIGNEE] |
| | |
| By: | |
| | Title: |
| | |
[Consented to and]10 Accepted: | |
| | |
BANK OF AMERICA, N.A., as Administrative Agent | |
| |
By: | | |
| Title: | |
| | |
[Consented to:]11 | |
| | |
By: | | |
| Title: | |
10To be added only if the consent of the Administrative Agent is required by the terms of the Credit Agreement.
11To be added only if the consent of the Borrower and/or other parties (e.g. L/C Issuer) is required by the terms of the Credit Agreement.
D-6
Form of Assignment and Assumption Agreement
ANNEX 1 TO ASSIGNMENT AND ASSUMPTION
Multi-Year $1,500,000,000 Credit Agreement
among St. Jude Medical, Inc.,
the Lenders party thereto and
Bank of America, N.A., as Administrative Agent and L/C Issuer
STANDARD TERMS AND CONDITIONS FOR
ASSIGNMENT AND ASSUMPTION
1. Representations and Warranties.
1.1. Assignor.[The][Each] Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of[the][[the relevant] Assigned Interest, (ii)[the][such] Assigned Interest is free and clear of any lien, encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby; and (b) assumes no responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement or any other Loan Document, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Loan Documents or any collateral thereunder, (iii) the financial condition of the Borrower, any of its Subsidiaries or Affiliates or any other Person obligated in respect of any Loan Document or (iv) the performance or observance by the Borrower, any of its Subsidiaries or Affiliates or any other Person of any of their respective obligations under any Loan Document.
1.2. Assignee.[The][Each] Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it meets all the requirements to be an assignee underSection 10.06(b)(iii) and(v) of the Credit Agreement (subject to such consents, if any, as may be required underSection 10.06(b)(iii) of the Credit Agreement), (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of[the][the relevant] Assigned Interest, shall have the obligations of a Lender thereunder, (iv) it is sophisticated with respect to decisions to acquire assets of the type represented by[the][such] Assigned Interest and either it, or the Person exercising discretion in making its decision to acquire[the][such] Assigned Interest, is experienced in acquiring assets of such type, (v) it has received a copy of the Credit Agreement, and has received or has been accorded the opportunity to receive copies of the most recent financial statements delivered pursuant toSection 6.01 thereof, as applicable, and such other documents and information as it deems appropriate to make its own credit analysis and decision to enter into this Assignment and Assumption and to purchase[the][such] Assigned Interest, (vi) it has, independently and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Assignment and Assumption and to purchase[the][such] Assigned Interest, and (vii) if it is a Foreign Lender, attached hereto is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and
D-7
Form of Assignment and Assumption Agreement
executed by[the][such] Assignee; and (b) agrees that (i) it will, independently and without reliance upon the Administrative Agent,[the][any] Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Loan Documents, and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Loan Documents are required to be performed by it as a Lender.
2. Payments. From and after the Effective Date, the Administrative Agent shall make all payments in respect of[the][each] Assigned Interest (including payments of principal, interest, fees and other amounts) to[the][the relevant] Assignor for amounts which have accrued to but excluding the Effective Date and to[the][the relevant] Assignee for amounts which have accrued from and after the Effective Date.
3. General Provisions. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns. This Assignment and Assumption may be executed in any number of counterparts, which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Assignment and Assumption by telecopy shall be effective as delivery of a manually executed counterpart of this Assignment and Assumption. This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York.
D-8
Form of Assignment and Assumption Agreement
EXHIBIT E
OPINIONS
See attached..
E-1
Opinions
December 22, 2010
The Lenders Parties to the Credit Agreement (as defined below)
In care of Bank of America, N.A.,
as Administrative Agent
101 N. Tryon Street
Mail Code: NC1-001-04-39
Charlotte, North Carolina 28255
Ladies and Gentlemen:
As General Counsel to St. Jude Medical, Inc., a Minnesota corporation (the “Company”), I am familiar with the affairs of the Company as they relate to the Multi-Year $1,500,000,000 Credit Agreement of even date herewith (the “Credit Agreement”) by and among the Company, Bank of America, N.A., as administrative agent (the “Agent”) and the lenders party thereto (the “Lenders”). This opinion is being furnished to you at the request of the Company pursuant to Section 4.01(a)(v) of the Credit Agreement. All capitalized terms used but not defined herein have the respective meanings given to such terms in the Credit Agreement.
In connection with this opinion, I or attorneys on my staff have examined and relied on originals or copies (certified or otherwise identified to our satisfaction) of all such documents, records, financial statements and papers of the Company, and certificates or comparable documents of public officials and officers, have consulted with such representatives of the Company and have made such investigations of fact and law as were deemed relevant or necessary as the basis for the opinions hereinafter expressed, and have examined executed original copies of the Credit Agreement.
I have not independently examined the records of any court or public office in any jurisdiction, and my opinion is subject to matters that examination of such records would reveal.
My opinions expressed below as to certain factual matters are qualified as being limited “to the best of my knowledge” or by other words to the same or similar effect. Such words, as used herein, mean that no contrary information came to my attention in connection with my representation of the Company. In rendering such opinions, I have not conducted any independent investigation of the Company. Finally, no inference as to my knowledge with respect to the factual matters upon which I have so qualified my opinions should be drawn from the fact of my representation of the Company.
The Lenders Parties to the Credit Agreement (as defined below)
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 2
| |
| In rendering the opinions expressed below, I have assumed without verification: |
| |
| (a) the authenticity of all documents submitted as originals; |
| |
| (b) the genuineness of all signatures (other than the signatures of signatories for the Company); |
| |
| (c) the legal capacity of natural persons executing the Credit Agreement on behalf of any party; and |
| |
| (d) the conformity to originals of all documents submitted to me as copies and the authenticity of the originals of such copies. |
Based upon the foregoing, and subject to the qualifications set forth below, I am of the opinion that:
|
1. The Company and its domestic Subsidiaries are corporations duly incorporated, validly existing and in good standing under the laws of the jurisdictions of their incorporation (except where the failure to be in good standing would not have a Material Adverse Effect), and have the power and authority to, and have all necessary governmental licenses, authorizations, consents and approvals to, own their assets and to carry on their respective businesses as currently conducted and as currently proposed to be conducted. |
|
2. The Company has the corporate power and authority to execute, deliver and perform its obligations under the Credit Agreement and the Notes and to borrow under the Credit Agreement. Such execution, delivery and performance and the borrowings under the Credit Agreement and the Notes: |
| |
| (a) have been duly authorized by all requisite corporate action of the Company; |
| |
| (b) do not violate any provision of the articles or certificate of incorporation or bylaws, both as amended to date, of the Company or require approval of its shareholders; |
| |
| (c) (i) to the best of my knowledge will not violate any order of any Governmental Authority, (ii) will not violate, result in a breach of or constitute (alone or with lapse of time or both) a default under the terms of any indenture, agreement, or other material instrument to which the Company is a party, or by which it or any of its property is bound, and (iii) will not result in the creation or imposition of any Lien upon, or with respect to, any of the properties or assets of the Company. |
The Lenders Parties to the Credit Agreement (as defined below)
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 3
| |
| 3. The Credit Agreement and the Notes have been duly authorized by the Company, and the Credit Agreement and the Notes delivered as of the date of this opinion have been executed and delivered by the Company. |
| |
| 4. No action, authorization, consent or approval of, registration or filing with, or any other action by, any Governmental Authority is required by the Company in connection with the execution and delivery of and performance by the Company of the Credit Agreement and the Notes and in connection with the loans made thereunder. |
| |
| 5. Neither the Company nor any of its Subsidiaries is an “investment company” as defined in or subject to regulation under the Investment Company Act of 1940 as amended. |
| |
| 6. To the best of my knowledge, there are no actions, suits or proceedings at law or in equity or by or before any governmental instrumentality or other agency now pending or threatened against or affecting the Company or any property or rights of the Company as to which there is a reasonable probability of an adverse determination and that, if adversely determined, would individually or in the aggregate materially impair the ability of the Company to perform its obligations under the terms of the Credit Agreement and the Notes or would reasonably be expected to have a Material Adverse Effect. |
The opinions expressed above are limited to the law of the State of Minnesota and the federal laws of the United States of America.
This letter is furnished solely for the benefit of the addressees hereof, and any participants or assigns thereof permitted under Section 10.06 of the Credit Agreement, in connection with the transactions referred to in the Credit Agreement, may not be relied upon by such addressees or by such permitted participants and assigns for any other purpose, and may not be relied upon or used by, circulated to, quoted by, or referred to, nor may copies hereof be delivered to, any other person without my prior written approval; provided, that a copy may be provided to the extent required by applicable law or regulation or in accordance with any auditing or oversight function or request by regulatory authorities to which any addressee or permitted participant or assignee is subject.
The Lenders Parties to the Credit Agreement (as defined below)
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 4
| |
| Very truly yours, |
| General Counsel,
|
| St. Jude Medical, Inc. |
December 22, 2010
The Lenders Parties to the Credit Agreement (as defined below)
In care of Bank of America, N.A.,
as Administrative Agent
101 N. Tryon Street
Mail Code: NC1-001-04-39
Charlotte, North Carolina 28255
Re: Credit Agreement
Ladies and Gentlemen:
We have acted as special counsel to St. Jude Medical, Inc., a Minnesota corporation (the “Company”), in connection with a Multi-Year $1,500,000,000 Credit Agreement of even date herewith (the “Credit Agreement”) by and among the Company, Bank of America, N.A., as administrative agent (the “Agent”), and the lenders party thereto (the “Lenders”). This opinion is being furnished to you at the request of the Company pursuant to Section 4.01(a)(v) of the Credit Agreement. All capitalized terms used but not defined herein have the respective meanings given to such terms in the Credit Agreement.
In rendering the opinions expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction, of the Credit Agreement and such other documents and reviewed such questions of law as we have considered necessary or appropriate. As to various questions of fact relevant to such opinions we have relied exclusively, without investigation, upon representations and certificates of officers or employees of the Company and other appropriate persons. In rendering our opinions set forth below, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures, and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons and that all parties to all agreements or instruments relevant hereto (including the Company) are duly incorporated or organized, validly existing and in good standing under the laws of their respective states of incorporation. We have also assumed that all such parties (including the Company) had the requisite power and authority (corporate or otherwise) to execute, deliver and perform the Credit Agreement and all other agreements or instruments relevant hereto, and that all such agreements or instruments have been duly authorized by all requisite action (corporate or otherwise) and duly executed and delivered by the parties thereto. We have also assumed that the Credit Agreement and all other agreements or instruments relevant hereto are the valid, binding and enforceable obligations of all parties thereto other than the Company. We have also assumed that (i) the Company is engaged in the business of manufacture and sale of medical devices, (ii) the Agent and the Lenders will be entering into the Credit Agreement in the ordinary
The Lenders Parties to the Credit Agreement
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 2
course of business, and (iii) all authorizations, approvals and consents of, and all filings and registrations with, any Governmental Authority (other than the State of New York) required on the part of the Company for the execution, delivery or performance by it of the Credit Agreement and the Notes have been duly obtained, made or effected, as the case may be, by or on behalf of it.
Based upon and subject to the foregoing and subject to the exceptions and qualifications set forth below, we are of the opinion that:
| |
| 1. The Credit Agreement constitutes and, upon execution and delivery of a Note upon the request therefor by a Lender, such Note will constitute, the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms thereof. |
| |
| 2. No authorization, approval or consent of, and no filing or registration with, any governmental or regulatory authority or agency of the State of New York is required on the part of the Company for the execution, delivery or performance by it of the Credit Agreement and the Notes. |
| |
| 3. The execution, delivery and performance by the Company of the Credit Agreement do not, and of the Notes will not, violate any applicable statute, rule or regulation of the State of New York. |
| |
| 4. The execution and delivery of the Credit Agreement and the borrowing and repayment of debt pursuant to the Credit Agreement will not violate or cause a breach of Regulation U of the Board of Governors of the Federal Reserve System. |
| |
| The opinions set forth above are subject to the following qualifications and exceptions: |
| |
| (a) Our opinion in paragraph 1 above is subject to the effect of applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer or similar laws of general application affecting creditors’ or secured creditors’ rights, and to the effect of general principles of equity, including, without limitation, concepts of materiality, diligence, reasonableness, good faith and fair dealing, election of remedies, estoppel and other similar doctrines affecting the enforceability of agreements generally in any proceeding in equity or at law. |
The Lenders Parties to the Credit Agreement
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 3
| |
| (b) The enforceability of provisions in the Credit Agreement and the Notes to the effect that terms may not be waived or modified except in writing may be limited under certain circumstances. |
| |
| (c) The availability of specific performance, injunctive relief and other equitable remedies is subject to the discretion of the tribunal before which any proceeding therefor may be brought. |
| |
| (d) We express no opinion as to the enforceability of provisions of the Credit Agreement or the Notes (i) to the extent they contain cumulative remedies to the extent such cumulative remedies purport to compensate, or would have the effect of compensating, the party entitled to the benefits thereof in an amount in excess of the actual loss suffered by such party, (ii) to the extent they contain obligations of the Company to pay any prepayment premium, default interest rate or early termination fee, if the payment of such premium, interest rate or fee may be construed as unreasonable in relation to actual damages or disproportionate to actual damages suffered by the Lenders as a result of such prepayment, default or termination, or (iii) purporting to establish evidentiary standards. |
| |
| (e) We express no opinion as to the enforceability of any provision contained in the Credit Agreement or the Notes allowing any loan participant to set off and apply the Company’s deposits with such participant against the Company’s Obligations. |
| |
| (f) We express no opinion as to the enforceability of provisions of the Credit Agreement or the Notes to the extent they contain waivers by the Company of any constitutional rights or remedies (other than waivers of right to trial by jury). |
| |
| (g) We express no opinion as to the enforceability of provisions of the Credit Agreement or the Notes to the extent they contain (i) choice of law or forum selection provisions, (ii) grants of powers of attorney, or (iii) terms purporting to establish evidentiary standards. |
| |
| (h) We express no opinion as to compliance or the effect of noncompliance by the Agent and the Lenders with any state or federal laws or regulations applicable to any of them in connection with the transactions described in the Credit Agreement. |
The Lenders Parties to the Credit Agreement
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 4
| |
| (i) Notwithstanding certain language of the Credit Agreement, the Agent and the Lenders may be limited to recovery of only reasonable expenses or attorney fees and legal expenses with respect to the enforcement of the Credit Agreement. |
| |
| (j) We express no opinion with respect to the effect of the federal securities laws and regulations administered by the Securities and Exchange Commission, or state “Blue Sky” laws and regulations, on the enforceability of the Credit Agreement. |
| |
| (k) Our opinion in paragraph 1 above, insofar as it relates to the enforceability of indemnification provisions set forth in the Credit Agreement or the Notes, is subject to the effect of federal and state securities laws and public policy relating thereto. |
| |
| (l) We express no opinion with respect to the enforceability of any provision of the Credit Agreement or the Notes that purports to excuse the Agent or any Lender from liability for, or require the Company to indemnify the Agent or any Lender against any liability arising out of, the gross negligence or willful misconduct of the Agent or any Lender. |
| |
| (m) In rendering our opinion in paragraph 2 above, we do not express any opinion with respect to any authorization, approval, consent, filing or registration with any governmental or regulatory authority or agency required generally in connection with the business or operations of the Company. |
The foregoing opinions are limited to matters involving the laws of the State of New York and, as to our opinions in paragraph 4, the federal laws of the United States of America. We express no opinion as to any matter other than as expressly set forth above, and no other opinion may be implied or interpreted herefrom. Our opinions are rendered only with respect to such laws that are currently in effect, and we disclaim any obligation to advise you of any change in law or fact that occurs after the date hereof.
This letter is furnished by us solely for the benefit of the addressees hereof and any participants or assigns thereof permitted under Section 10.06 of the Credit Agreement, in connection with the transactions referred to in the Credit Agreement, and may not be relied upon by such addressees or by such permitted participants and assigns for any other purpose; such permitted reliance shall not, however, imply or establish an attorney-client relationship between such relying party and this firm with respect to the Credit Agreement or any Note or the transactions contemplated therein, and such relying party, by relying on our opinion, disclaims any such attorney-client relationship with respect to the Credit Agreement or any Note or the
The Lenders Parties to the Credit Agreement
In care of Bank of America, N.A.,
as Administrative Agent
December 22, 2010
Page 5
transactions contemplated therein. This opinion letter may not be relied upon or used by, circulated to, quoted by, or referred to, nor may copies hereof be delivered to, any other person without our prior written approval; provided, that a copy may be provided to the extent required by applicable law or regulation or in accordance with any auditing or oversight function or request by regulatory authorities to which any addressee or permitted participant or assignee is subject.
MKP/SK